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ABSTRACT 
 
Transforming growth factor beta (TGFβ) superfamily signaling regulates multiple 
reproductive events. However, the in vivo role of the TGFβ signaling in uterine 
development and function is not well defined. Conditional knockout (cKO) of TGFβ 
receptor 1 (TGFBR1) in the female reproductive tract leads to remarkable smooth 
muscle defects. The first study of this dissertation research was to further define the role 
of TGFβ signaling in uterine development. We found that the myometrial defects 
in Tgfbr1 cKO mice were associated with dysregulated expression of key extracellular 
matrix components and platelet-derived growth factors signaling during a critical time 
window of early postnatal uterine development. To complement the loss of function 
model, in the second study, we generated a uterine specific gain-of-function mouse 
model harboring a constitutively active TGFBR1 which leads to over-activation of TGFβ 
signaling. Constitutive activation of TGFBR1 caused infertility and defects in uterine 
morphology and function, as evidenced by abnormal myometrial structure, dramatically 
reduced numbers of uterine glands, and impaired uterine decidualization. These studies 
underscore the importance of a balanced TGFβ signaling system in establishing a uterine 
microenvironment conducive to normal development and function. In the third study of 
this dissertation research, we focused on identifying the role of TGFβ signaling in 
PTEN-inactivated uterine epithelial cells. Depletion of PTEN in the mouse uterus causes 
endometrial cancer. We found that simultaneous deletion of Tgfbr1 and Pten in the 
mouse uterus caused severe endometrial lesions and pulmonary metastases compared 
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with deletion of Pten alone. The development of metastasis and accelerated tumor 
progression in the Pten/Tgfbr1 double knockout mice was linked to increased production 
of pro-inflammatory chemokines, enhanced cancer cell motility evidenced by 
myometrial invasion and disruption, and an altered tumor microenvironment 
characterized by recruitment of tumor-associated macrophages. Our results suggest that 
TGFβ signaling synergizes with PTEN to suppress the progression of endometrial 
cancer. 
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1. INTRODUCTION AND LITERATURE REVIEW 
 
1.1 Transforming growth factor beta (TGFβ) superfamily signaling 
The discovery of TGFβ dates back to the 1970s to 1980s [1, 2]. In 1978, de Larco and 
Todaro found that murine sarcoma virus-transformed mouse fibroblasts produced a 
polypeptide growth factor, sarcoma growth factor (SGF), that promoted cell growth in 
soft agar [3]. In 1981, SGF was found to be a mixture of at least two distinct substances, 
including TGFα and TGFβ [4, 5]. Subsequently, TGFβ1 was purified from human 
platelets [6] and its cDNA cloned [7]. 
 
Shortly after the discovery of TGFβ1, other proteins were discovered that shared 
sequence homology with TGFβ1, such as inhibin, Müllerian inhibiting substance/anti-
Müllerian hormone (MIS/AMH), and bone morphogenetic proteins (BMPs) [8-13]. 
Currently, there are more than 40 proteins functioning as ligands for TGFβ superfamily 
signaling, including TGFβs, BMPs, growth differentiation factors (GDFs), activins, 
inhibins, AMH, and the most distantly related glial cell-derived neurotrophic factors 
(GDNFs) [14, 15]. This introduction will mainly focus on TGFβ signaling. 
 
1.1.1 TGFβ isoforms synthesis and activation 
TGFβ ligands (TGFβ1, TGFβ2, and TGFβ3) are synthesized as pre-pro-peptides 
containing an N-terminal signal peptide, a latency-associated peptide (LAP), and a C-
terminal region [16-18]. The signal peptide is necessary for translocation to the cell 
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membrane and can be cleaved by a signal peptidase, yielding a pro-peptide of TGFβ [16, 
19]. LAP is cleaved from the pro-TGFβ by furin convertase, but still noncovalently 
interacts with the disulfide-linked TGFβ homodimers to form the small latent complex 
(SLC) [20, 21]. A latent TGFβ-binding protein (LTBP) binds to the SLC to form a large 
latent complex (LLC), which will be secreted into the extracellular matrix compartment 
[17, 20]. Several substances are responsible for the release or exposure of the 
biologically active TGFβ. The substances include plasmin, matrix metalloproteinase 2 
(MMP2), MMP9, thrombospondin 1 (TSP1), reactive oxygen species (ROS), integrin 
αvβ6, and integrin αvβ8. In addition, physical conditions such as extreme pH, 
temperature, and radiation also influence the activation of TGFβ by promoting the 
release of mature TGFβ [17, 22-35]. 
 
1.1.2 TGFβ receptors 
TGFβ superfamily ligands, except GDNFs that utilize a tyrosine kinase receptor, activate 
the intracellular signaling cascades via the transmembrane serine-threonine kinases 
receptors [36-38]. Based on their structures and functions, TGFβ superfamily receptors 
are classified into three types [9, 39]. Type I and type II receptors, the major receptors 
for TGFβ superfamily members [40], are single-transmembrane proteins containing an 
extracellular domain, a transmembrane domain, and a cytoplasmic serine-threonine 
kinase domain [41]. The Type III receptor (or betaglycan) is a membrane-anchored 
proteoglycan that facilitates the binding of ligands to the type II receptors [40, 42, 43]. 
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There are seven type I receptors in mammals, namely activin receptor-like kinase 1 
(ALK1), ALK2, ALK3, ALK5, ALK6, and ALK7 [14, 44]. The alternative names for 
the type I receptors are listed in Table 1. Type I receptors contain a highly conserved 
region (i.e., GS domain), which is characterized by the presence of a SGSGS sequence 
[45]. Phosphorylation of the GS domain by type II receptors induces the intra-cellular 
responses, while GS domain mutations may lead to constitutive activation of type I 
receptors [45-51]. Among the seven type I receptors, TGFBR1 is the major receptor that 
propagates the signal of TGFβ ligands, although ACVRL1 and ACVR1 can also be 
activated by TGFβ in mouse embryonic endothelial cells and human endothelial cells, 
respectively [45, 52, 53].  
 
Table 1. Two nomenclature systems for the TGFβ type I receptors 
 
Activin receptor-like kinases 
nomenclature system 
Alternative nomenclature system 
Activin receptor-like kinase 1 (ALK1) Activin A receptor-like type 1 (ACVRL1) 
Activin receptor-like kinase 2 (ALK2) Activin A receptor type 1 (ACVR1) 
Activin receptor-like kinase 3 (ALK3) BMP receptor 1A (BMPR1A) 
Activin receptor-like kinase 4 (ALK4) Activin A receptor type 1B (ACVR1B) 
Activin receptor-like kinase 5 (ALK5) TGFβ receptor 1 (TGFBR1) 
Activin receptor-like kinase 6 (ALK6) BMP receptor 1B (BMPR1B) 
Activin receptor-like kinase 7 (ALK7) Activin A receptor type 1C (ACVR1C) 
 
Five type II receptors have been identified in mammalian species, including ACVR2, 
ACVR2B, AMH receptor 2 (AMHR2), BMPR2, and TGFBR2 [14, 44]. Type II 
receptors are constitutively active. Upon ligand binding, they phosphorylate and activate 
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type I receptors [45, 54, 55]. Among the five type II receptors, TGFBR2 mediates TGFβ 
signaling [45]. It has been suggested that TGFβ1 and TGFβ3 bind to TGFBR2 with a 
high affinity in the absence of TGFBR1, but TGFβ2 only binds to TGFBR2 when 
TGFBR1 is present in human fibroblast cells [56, 57].  
 
Type III receptor TGFBR3 i.e., betaglycan, is a co-receptor which presents the TGFβ 
ligands to TGFBR2 [58]. It has a large N-terminal extracellular domain for 
glycosaminoglycan attachment and TGFβ binding, a single transmembrane domain, and 
a small cytoplasmic domain interacting with TGFBR2 to enhance the TGFβ signaling 
[42, 43, 59, 60]. TGFBR3 not only increases the responsiveness of TGFBR2 to TGFβ2 
[42, 43, 61], but also that of ACVR2 to inhibin [43, 62]. A membrane glycoprotein 
endoglin (CD105), which shares high homology (63%) to the TGFBR3 in the 
transmembrane and cytoplasmic domain, has also been identified as a co-receptor for 
TGFβ, particularly, TGFβ1 and TGFβ3 [40, 63]. 
 
1.1.3 SMAD proteins 
Sma and Mad (mother against decapentaplegic)-related proteins (SMADs) are the 
intracellular transducers of canonical TGFβ superfamily signaling [64, 65]. Mammalian 
SMAD proteins (i.e., SMAD1, 2, 3, 4, 5, 6, 7, and 9) can be classified into receptor-
regulated SMADs (R-SMADs; SMAD1/2/3/5/9), common SMAD (Co-SMAD; 
SMAD4), and inhibitory SMADs (I-SMADs; SMAD6/7). R-SMADs and co-SMAD 
comprise two conserved domains [i.e., the N-terminal Mad Homology 1 (MH1) domain 
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and the C-terminal MH2 domain] connected by a variable linker region [66]. The MH1 
domain binds to the SMAD-binding element (SBE) and it is implicated in gene 
regulation [67]. The MH2 domain mediates protein-protein interactions and is involved 
in the SMAD-receptor interaction [68], the binding of R-SMAD to the SMAD anchor 
for receptor activation (SARA) [69], the oligomerization of R-SMADs and co-SMAD 
[70, 71], and the association of SMADs with transcriptional coactivators [72]. In 
addition, R-SMADs have a Ser-Ser-X-Ser (SSXS) motif which can be phosphorylated 
by type I receptors [73-75]. Co-SMAD does not possess the SSXS motif and, therefore, 
does not bind to type I receptors [76]. In contrast to R-SMADs and co-SMAD, I-SMADs 
have a conserved MH2 domain, but divergent MH1 domain and linker region [77]. In 
general, SMADs 1/5/9 transduce BMP signaling while SMADs 2/3 mediate 
TGFβ/activin signaling [64, 65]. Although both I-SMADs inhibit BMP signaling, 
SMAD7 can also target TGFβ signaling [78, 79].  
 
1.1.4 Canonical and non-canonical TGFβ superfamily signaling 
The canonical TGFβ superfamily signaling is induced when ligand-receptor complexes 
form [14, 40, 44]. Within the complex, the Type II receptor phosphorylates and activates 
the type I receptor, which in turn phosphorylates the R-SMADs. R-SMADs bind to 
SMAD4, enter the nucleus, and regulate the expression of down-stream target genes. 
Figure 1 illustrates the canonical, or SMAD-dependent, TGFβ superfamily signaling 
pathways.   
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Figure 1. Canonical TGFβ superfamily signaling pathway. The canonical TGFβ 
superfamily signaling is induced by ligands binding to their receptor complex. The 
activated receptor complex phosphorylates receptor-regulated SMADs (i.e., SMAD2/3 
and SMAD1/5/9) which then bind to the common SMAD (i.e., SMAD4) and translocate 
into the nucleus to regulate the expression of downstream targets. SMADs 2/3 and 
SMADs 1/5/9 transduce TGFβ/activin and BMP signaling, respectively. TGFβ 
superfamily signaling pathways are negatively regulated by the ligand-binding proteins 
(e.g. follistatin, gremlin and noggin) and inhibitory SMADs (i.e., SMAD6 and SMAD7). 
  
The canonical TGFβ superfamily signaling has been shown to cross-talk with a variety 
of signaling pathways including, but not limited to, mitogen-activated protein kinase 
(MAPK), phosphatidylinositol-3 kinase (PI3K)/AKT, WNT, Hedgehog, Notch, Hippo, 
nuclear factor κB (NF-κB), Janus kinase/signal transducers and activators of 
transcription (JAK/STAT), interleukin (IL)/interferon gamma (IFNγ)/tumor necrosis 
factor alpha (TNFα) cytokines, and microRNA (miRNA) machinery (reviewed in [80-
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83]). The interaction between TGFβ superfamily signaling and other signaling pathways 
may lead to either synergistic or antagonistic effects on signaling outcome.  
 
 
 
Figure 2. Non-canonical TGFβ superfamily signaling pathways. The canonical pathway 
is SMAD-dependent (Left). The non-canonical pathway is SMAD-independent (Right), 
such as RAS-RAF-MERK1/2-ERK1/2, TAK1-MMK3/6-P38, TAK1-MMK4-JNK and 
PI3K-AKT pathways.  
 
The non-canonical TGFβ superfamily signaling pathways are SMAD independent, such 
as ERK, P38, JNK and PI3K/AKT pathways (Figure 2). ERK, P38 and JNK belong to 
the MAPK family. For ERK signaling, extracellular mitogens bind to membrane 
receptor and serially activate the intracellular kinase cascades of GTPase RAS, RAF, 
MEK1/2, and then ERK1/2 [84-86]. TGFβ can induce a rapid activation of RAS in rat 
intestinal epithelial cells and mink lung epithelial cells [87]. Activation of ERK1/2 by 
TGFβ can occur in various cell types [88-90]. Activation of transforming growth factor 
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beta-activated kinase 1 (TAK1) by TGFβ and BMP [91] leads to the activation of 
MKK3/6-P38 and MKK4-JNK signaling pathways [92, 93]. The MAPK signaling 
cascades are key regulators of TGFβ induced epithelial to mesenchymal transition 
(EMT) [94-96]. PI3K/AKT signaling is known to regulate cell proliferation and survival 
[97, 98]. TGFβ activates PI3K/AKT signaling via non-canonical signaling [99-101], and 
PI3K inhibitor LY294002 prevents TGFβ induced AKT activation and cell migration 
[101]. 
 
1.2 TGFβ superfamily signaling in the uterus 
The uterus is a key reproductive organ that supports pregnancy. The endometrial layer of 
the uterus consists of luminal and glandular epithelia and surrounding endometrial 
stroma and plays an important role in development of the conceptus (embryo and its 
extra-embryonic membranes). Under the influence of steroid hormones and growth 
factors, the endometrium undergoes cyclic remodeling during the estrous cycle in mice 
or menstrual cycle in humans [102, 103]. The normal functional luminal epithelium is 
critical for attachment and implantation of blastocysts [104]. Secretions from the uterine 
epithelium, such as leukemia inhibitory factor (LIF) [105] and mucin 1 (MUC1) [106],  
play essential roles in conceptus development during pregnancy. Meanwhile, 
endometrial glands provide an important source of nutrients and growth factors for 
establishing a successful pregnancy [107]. Endometrial stromal cells produce growth 
factors and undergo decidualization to support implantation and conceptus development 
in some species including primates and rodents [108]. The myometrium is composed 
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primarily of smooth muscle cells, which contain contractile machinery that is tightly 
regulated during pregnancy and parturition by many factors such as hormones [109, 
110], ion channels [111-114], nitric oxide [115-118], and microRNAs [119].  
 
1.2.1 Uterine development 
The uterus develops from the Müllerian duct during embryogenesis and the 
developmental events continue after birth. In mice, Müllerian ducts form via 
invagination of the coelomic epithelium around embryonic Day 11.75 [107, 120]. At 
birth, the uteri of mice consist of a simple epithelium surrounded by undifferentiated 
mesenchyme [107, 121]. Between birth and postnatal day 3 (PD3), smooth muscle cells 
differentiate from the mesenchyme and start to form the inner circular myometrial layer, 
which is evident by PD5 [121, 122]. By PD10, longitudinal smooth muscle layers form 
bundle-like structures. The uterus acquires its basic myometrial structure by PD15 [121]. 
Myometrial development is regulated/influenced by hormonal, cellular, and molecular 
signals [123-128]. Estrogen seems to play a role in regulating the development of the 
circular myometrium [123]. Tamoxifen-treated neonatal mice have a disorganized 
circular myometrium with reduced laminin expression and they develop a uterine 
pathology reminiscent of adenomyosis, with the presence of uterine glands within the 
myometrium [123]. However, mice treated with estradiol develop intact but 
hypertrophied muscle layers [123]. Additionally, the WNT/beta-catenin signaling 
pathway regulates mouse uterine development [124-127]. Wnt-7a mutant female mice 
develop abnormal oviducts and uteri, and smooth muscle defects are prominent in their 
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uteri [124, 127]. Forkhead box L2 (Foxl2) also acts through WNT signaling to regulate 
uterine maturation and mice with conditional deletion of Foxl2 in the uterus develop a 
hypertrophic, disorganized inner myometrial layer [128]. However, key signaling 
pathways that govern myometrial development remain to be defined. 
Accompanying myometrial formation is adenogenesis, a process whereby endometrial 
glands develop [129-131]. Adenogenesis occurs via invagination of uterine luminal 
epithelium after PD5 in mice [131]. Uterine glands are essential for fertility and 
pregnancy in several species [132]. Despite the well-established role of uterine glands in 
reproduction and the recent progress in identifying adenogenesis-associated genes such 
as forkhead box A2 (Foxa2), Wnt4, Wnt5a, Wnt7a, and cadherin 1 (Cdh1) [124, 127, 
133-137], mechanisms underlying the development of uterine glands are not well 
defined. Of note, the proliferation of uterine epithelial cells is critical for uterine 
development and function. Abnormal proliferation of uterine epithelial cells results in 
endometrial hyperplasia or cancer. 
1.2.2 The expression and function of TGFβ superfamily members in the uterus 
TGFβ superfamily members are key regulators of female reproductive events, such as 
follicular development, ovulation, oocyte-cumulus cell communications, implantation 
and development of the blastocyst/conceptus, uterine decidualization, and placentation 
[138-151]. TGFβ receptors, and SMADs, are signaling components, including TGFβ 
ligands, expressed in the myometrial cells of mice and humans and regulate DNA 
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synthesis in human myometrial cells [152-154]. In the rat uterus, myometrial expression 
of TGFβ1 and TGFβ3 is increased during mid-gestation, with TGFβ3 strongly localized 
to the circular myometrial layer during late pregnancy [155]. In human endometria, 
TGFβs, TGFBR2 and SMAD2/3 mRNAs and proteins are express in both stromal cells 
and epithelia [156, 157]. In the endometrium of prepubertal mice, expression of TGFβ 
ligands is increased by diethylstilbestrol [158]. Smad2 and Smad4 mRNAs are 
predominately localized in mouse uterine epithelial cells during the estrous cycle and 
pre-implantation period, but in decidual cells after blastocyst implantation [159]. The 
mRNA transcripts of BMP ligands and receptors are expressed in rat and mouse uteri 
[160, 161]. BMP2 and BMP4 proteins are localized in the mouse endometrium and 
myometrium with the highest expression in epithelial cells [160, 162]. Results of tissue 
microarrays demonstrate the dynamic expression of BMP ligands, receptor, and SMADs 
in human endometrium [163]. Phospho-SMADs 1/5/9 (pSMADs 1/5/9) are detected in 
the endometrium and myometrium of mice [162]. In addition, other TGFβ superfamily 
members such as activin, inhibin, and myostatin are also expressed in human and murine 
uteri [164-169]. 
The expression of TGFβ superfamily components in the uterus indicates that TGFβ 
superfamily signaling may play a role in uterine development and function. However, 
the embryonically lethal phenotype of most TGFβ superfamily members prevents 
understanding of their in vivo functions in the uterus (reviewed in [14, 170]). The 
application of the Cre-LoxP system to generate conditional knockout (cKO) mice 
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overcomes this difficulty (Table 2). Two Cre mouse models, anti-Mullerian hormone 
receptor type 2 (Amhr2)-Cre and progesterone receptor (Pgr)-Cre are commonly used to 
study gene function in the uterus. Amhr2-Cre is expressed in uterine stromal cells and 
myometrial cells [171]. Pgr-Cre deletes genes in uterine epithelia, stromal cells, and 
myometrial cells [172].  
Table 2. Uterine defects in mouse models with conditional deletion of TGFβ 
superfamily members 
Mouse models Fertility and defects in uterine development and function 
Ligands 
Bmp2; Pgr-
Cre 
Infertility; failure in formation of implantation sites due to impaired 
decidualization [173] 
Nodal; Pgr-
Cre 
Subfertility; placental defects due to malformation of the maternal 
decidua basalis [174] 
Receptors 
Bmpr2; Pgr-
Cre 
Infertility; multiple defects during decidualization and placentation 
including impaired decidual cell proliferation and differentiation, 
attenuated trophoblast invasion, compromised vascularization and 
spiral artery remodeling, as well as depletion of uNK cells [147] 
Acvr1; Pgr-
Cre 
Infertility; delayed implantation and defective stromal cell 
decidualization [175] 
Bmpr1a; Pgr-
Cre 
Infertility; nonreceptive luminal uterine epithelium with increased 
microvilli density and cell polarity, defective decidualization [176] 
Acvr1b; Pgr-
Cre  
Subfertility; similar phenotype to Nodal, Pgr-Cre [177] 
Tgfbr1; Pgr-
Cre 
Subfertility; delayed implantation and defects in lumen closure, uNK 
cell differentiation, spiral artery remodeling, and placentation [178] 
Tgfbr1; 
Amhr2-Cre 
Infertility; disrupted uterine smooth muscle development; 
endometrial hyperplasia in aged mice [179, 180] 
Bmpr1b Infertility; endometrial developmental defects including thinner 
stromal layer and underdeveloped or absent endometrial glands [181]
SMADs 
SMAD1/5/4; 
Amhr2-Cre 
Infertility; disorganized myometrium and hyperplastic epithelium; 
defective implantation and decidualization [182] 
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Conditional deletion of Tgfbr1 by Amhr2-Cre showed that TGFβ signaling is essential 
for maintaining the integrity of the female reproductive tract [179]. The Tgfbr1 Amhr2-
Cre cKO mice are infertile and develop bilateral oviductal diverticula, leading to 
infertility. Of note, smooth muscle defects are evident in the reproductive tract, including 
the oviduct and uterus [179]. These mutant mice also have enhanced uterine epithelial 
cell proliferation, which culminates in endometrial hyperplasia, presumably due to 
altered paracrine growth factor signaling [180]. Interestingly, conditional deletion of 
Smad1/5/4 using Amhr2-Cre leads to the formation of oviductal diverticula as well as 
disorganized myometrium and hyperplastic uterine epithelia [182].  
Under the regulation of estrogen and progesterone, endometrial stromal cells 
differentiate into decidual cells to prepare for implantation of the blastocyst and 
development of the conceptus [183]. Decidualization in the human occurs in the late 
secretory phase of menstrual cycle, while in the mouse, decidualization is induced by the 
implanting blastocysts and can be artificially induced by mechanical stimulation [183]. 
Placentation, the formation of a placenta, is another critical physiological process that is 
indispensable for conceptus development; malfunction of the placenta results in fetal 
growth restriction and fetal death [184, 185]. TGFβ superfamily members including 
TGFβ, BMP, activin and inhibin are expressed in the uterus during the peri-implantation 
period [186-190]. Administration of anti-TGFβ1 antibody into the murine uterine lumen  
reduces the number of implanted blastocysts [191]. Conditional knockout of Tgfbr1 with 
Pgr-Cre results in delayed implantation of blastocysts, shallow trophoblast invasion, and 
14 
uterine lumen closure defects [178]. The different phenotypes of Tgfbr1 Amhr2-Cre and 
Tgfbr1 Pgr-Cre cKO mice suggest that the role of TGFβ receptor signaling in the uterus 
is time and cell type dependent. In humans, TGFβ signaling regulates decidualization of 
the endometrial stromal cells and trophoblast differentiation and invasion [192-194].  
BMP signaling is required for implantation, decidualization, and placentation as 
demonstrated using several cKO mouse models. Bmp2 Pgr-Cre cKO females show 
impaired decidualization, which is linked to dysregulated WNT signaling, PGR, and 
prostaglandin synthase 2 (Ptgs2) [173]. BMP2 also regulates human endometrial stromal 
cell decidualization though WNT signaling [195]. Conditional inactivation of Bmpr2 
using Pgr-Cre causes defects in decidual cell proliferation, decidual vascularization, 
trophoblast differentiation and invasion, and uterine natural killer (uNK) cell recruitment 
[147]. These defects result in severe hemorrhage and intrauterine growth retardation, 
leading to pregnancy loss during mid-gestation [147]. ACVR1 mediates signaling 
induced by BMP, activin, and TGFβ [53, 196, 197]. Conditional ablation of Acvr1 using 
Pgr-Cre suppresses the expression of CCAAT/enhancer-binding protein β (Cebpb), a 
critical regulator of PGR, through SMAD1/5. The Acvr1 Pgr-Cre cKO mice show 
delayed implantation of blastocysts, impaired stromal cell decidualization, and sterility 
[175]. Conditional deletion of Bmpr1a using Pgr-Cre also results in infertility. The 
uterine luminal epithelium of Bmpr1a Pgr-Cre cKO mice has increased microvilli 
density, estrogen response, and cell proliferation, and maintains the polarity of apical 
epithelial cells during implantation [176]. Moreover, deletion of Bmpr1a in the uterus 
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reduces the expression of Kruppel-like factor 15 (Klf15), a transcription factor that 
inhibits epithelial cell proliferation during implantation through SMAD signaling [176, 
198]. In addition to the aforementioned myometrial and epithelial cell defects, 
Smads1/5/4 Amhr2-Cre cKO mice also have implantation failure, unclosed uterine 
lumen, and defective decidualization [182].  
Nodal signaling components expressed in the human endometrium are involved in tissue 
remodeling during the menstrual cycle, decidualization, and placentation [199-201]. In 
the murine uterus, Nodal expression is induced by blastocyst implantation and linked to 
decidualization and placentation [201]. Conditional deletion of Nodal using Pgr-Cre 
causes subfertility due to post-implantation placentation abnormalities and intrauterine 
growth restriction. Loss of Nodal in the uterus reduces proliferation and increases 
apoptosis in cells of the maternal decidua basalis and compromises placentation [174]. 
Nodal signals through ACVR1B and ACVR1C [202]. Conditional inactivation of 
Acvr1b using Pgr-Cre phenocopies the defects of Nodal Pgr-Cre cKO mice [177]. 
Acvr1b Pgr-Cre cKO mice display placental defects including expansion of trophoblast 
giant cells and reductions in spongiotrophoblast and labyrinth [177]. 
Activins and inhibins are expressed in human endometrium and placenta and may 
regulate decidualization and placentation [203, 204]. The aforementioned uterine defects 
[175, 177] (also see Table 2) demonstrated by conditional ablation of the type I receptors 
for activin, Acvr1 and Acvr1b, suggest a role of activin signaling in uterine functions. 
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1.2.3 TGFβ superfamily and uterine diseases 
TGFβ superfamily signaling has been explored in many common uterine diseases such 
as uterine fibroids, adenomyosis, and endometrial cancer (reviewed in [151, 170, 205, 
206]). Uterine fibroids, also known as leiomyomas, emerging from the myometrium, are 
the most common noncancerous tumors in the uterus. It is estimated that 5 to 70% 
women will have this disease during their lifetime and 15 to 30% of them may develop 
severe symptoms such as uterine bleeding, pelvic pain and miscarriage [180, 207, 208]. 
Expression of TGFβ ligands and receptors, activin A, and myostatin are higher in human 
leiomyoma versus myometrium during the secretory phase of the menstrual cycle [209, 
210]. The concentrations of TGFβ in serum are higher in women of childbearing age 
with uterine fibroids than healthy subjects [211]. TGFβ and activin signaling promote 
leiomyoma development via regulation of cell growth and uterine fibrinogenesis [212, 
213]. Treatment with TGFβ3 and activin A up-regulates extracellular matrix genes such 
as collagen 1A1, fibronectin 1 and versican in myometrial and/or leiomyoma cells [212- 
215]. Therefore, several drugs have been developed to target the enhanced TGFβ 
signaling in uterine fibroids, including gonadotropin-releasing hormone-analogs, 
tibolone and asoprisnil [216, 217]. 
Adenomyosis is defined by the presence of endometrial glands and stroma within the 
myometrium and may occur in 8 to 27% females [218, 219]. It has a negative effect on 
female fertility and may induce malignant conditions such as endometrial cancer [218-
220]. The etiology of adenomyosis is not clear. Ectopic endometrium from women with 
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adenomyosis has increased levels of TGFβ1 and pSMAD3 compared to control 
endometrium [221]. Consistently, tamoxifen induced adenomyosis in mice is associated 
with up-regulation of expression of TGFβ1 and pSMAD3 in the cytoplasm of ectopic 
epithelium, coinciding with epithelial–mesenchymal transition and fibroblast-to-
myofibroblast transdifferentiation [221]. Conditional deletion of Tgfbr1 using Amhr2-
Cre in uterine mesenchymal cells also causes adenomyosis [179]. In addition, expression 
of myostatin, activin A, follistatin, ACVR2, and ACVR2B mRNAs is greater in the 
adenomyotic nodule than in control endometrium, indicating that activin signaling may 
play a role in adenomyosis [222].  
 
As the most common gynecological cancer, endometrial cancer ranks fourth in female 
cancers within the USA [223]. Approximately 61,380 new cases and 10,920 deaths from 
uterine corpus cancers are projected to occur in 2017 in the United States, 92% of which 
are endometrial cancers [223]. Mutations affecting TGFβ signaling components 
including TGFβ receptors and SMADs and alterations in TGFβ signaling activity are 
reflected in changes in gene expression and/or phosphorylation of key signal transducers 
that may play a role in the pathoetiology of human endometrial cancer [205, 206]. 
TGFBR1 has a 5.6% mutation and alteration rate in human endometrial cancer [206, 
224-226]. Cancerous human endometrium has markedly lower levels of TGFBR1 
protein expression [227, 228]. TGFBR2 is mutated/altered in 6.5% endometrial tumors 
[206, 224-226]. The Cancer Genome Atlas (TCGA) studies suggested that the 
percentages of altered SMAD proteins are 13% for SMAD2, 7% for SMAD3, and 10% 
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for SMAD4 [206, 224-226]. Decreased expression of SMAD2 and SMAD4 mRNAs in 
invasive endometrial cancers versus non-infiltrating cancers were reported [229]. Of 
note, altered subcellular (i.e., cytoplasmic vs. nuclear) distribution of SMAD2 and 
SMAD4 may also play a role in endometrial cancer progression [229]. Moreover, 
immunoreactive signals of pSMAD2 are weak to undetectable in endometrial cancer 
samples compared with normal endometrium [228]. In addition, SMAD7, the inhibitory 
SMAD that serves as a negative modulator of TGFβ signaling, is altered in 10% of 
endometrial cancers, with mRNA up-regulation being the greatest change [206, 224-
226]. High SMAD7 expression also correlates with a shorter time to the recurrence of 
endometrial cancer [230].  
 
1.3 Aims and hypothesis 
The overall goal of this study is to understand the contributions of TGFβ signaling to 
maintain normal development and function of the uterus. Based on previous studies and 
literature, we hypothesize that TGFβ signaling is required for uterine development 
and function. Dysregulated TGFβ signaling will cause abnormal uterine cell 
proliferation and differentiation, leading to developmental defects in the uterus and 
reproductive failure. This hypothesis will be tested by addressing the following 
specific aims.  
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1.3.1 Specific aim 1: define the role of TGFβ signaling in uterine development 
We hypothesize that TGFβ signaling plays a key role in regulating myometrial 
development, which is indispensable for a successful pregnancy. The role of TGFβ 
signaling in myometrial development will be examined using mice with conditional 
deletion of Tgfbr1 by Amhr2-Cre. 
  
1.3.2 Specific aim 2: identify the effect of dysregulation of TGFβ signaling on 
uterine development and function    
We hypothesize that precisely controlled TGFβ signaling is conducive to uterine 
development and function, and that dysregulation of TGFβ signaling will lead to uterine 
defects resulting from altered proliferation/differentiation of uterine cells. We will use 
mice harboring constitutively active TGFBR1 to examine the consequences of enhanced 
TGFβ signaling in uterine development and function. 
 
1.3.3 Specific aim 3: identify the role of TGFβ signaling in PTEN-inactivated 
uterine epithelial cells  
We hypothesize that TGFβ signaling inhibits the migration/invasion of cancerous 
epithelial cells in PTEN-inactivated uteri. We will generate mice with conditional 
deletion of TGFBR1 in the PETN null uterus to determine the interactions between 
TGFβ signaling and PTEN/AKT signaling in cancerous epithelial cells. 
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1.3.4 Significance and rationale  
In the United States, approximately 6% (1.5 million) of married women aged 15 to 44 
were infertile between 2006 and 2010 [231]. Furthermore, about 12% (6.7 million) of all 
women aged 15 to 44 have impaired fecundity, that is, difficulty in either getting 
pregnant or carrying a pregnancy to give live birth [231]. Among this dramatic number 
of reproductive-aged women facing pregnancy loss and infertility, many of them are 
associated with uterine dysfunction and diseases. Therefore, understanding the 
underlying regulation and mechanisms of uterine development, function and diseases are 
of particular importance.  
 
Despite the evidence for expression of TGFβ signaling components in the uterus and the 
reported involvement of TGFβ signaling in uterine functions (reviewed in [151, 170]), 
the in vivo role of TGFβ signaling in the uterus remains elusive, partially because of the 
redundancy of the ligands [232, 233] and the lack of suitable animal models. Deletion of 
TGFβ ligands, TGFBR1, or TGFBR2 results in embryonic lethality or death in pups 
shortly after birth, preventing functional studies of TGFβ signaling in the mouse uterus 
during the postnatal period [234-239].  
 
TGFβ signaling is required for the integrity of the female reproductive tract [179]. The 
tissue/cell specific targeting approach for studying TGFβ signaling has been validated as 
an effective means to define gene function in the reproductive system [145, 147, 179, 
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240, 241]. Genetic manipulation of Tgfbr1 expression using the Cre-Lox method 
overcomes the issues of ligand redundancy and embryonic lethality due to global 
inactivation of individual TGFβ genes. The proposed study is expected to provide new 
mechanistic insights into the role of TGFβ signaling in uterine development, function, 
and diseases. These studies will have a potential impact on the development of new 
diagnostic and therapeutic strategies for mitigating fertility defects and uterine diseases 
associated with dysregulated TGFβ signaling. 
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2. TGFBR1 IS REQUIRED FOR MOUSE MYOMETRIAL DEVELOPMENT 
 
2.1 Introduction 
The uterus serves as an “incubator” of a new life in mammals [242]. It develops from the 
Müllerian duct, a tube formed via invagination of the coelomic epithelium during 
embryogenesis [107, 120]. Myometrium is composed primarily of smooth muscle cells 
or myocytes, which contain contractile machinery that is tightly regulated during 
pregnancy and parturition. The role of the myometrium in pregnancy-associated events 
has been well established. During pregnancy, the myometrial cells transform from a 
quiescent to a contractile phenotype. Myometrial contractility is regulated/influenced by 
hormonal, cellular, and molecular signals [109-112, 115, 116, 119, 243]. Structural and 
functional abnormalities of myometrium may lead to reproductive disorders, resulting in 
neonatal mortality and morbidity.  
 
In mice, myometrial development occurs after birth, and the uterus acquires all basic 
structures and configuration by postnatal day 15 (P15) [121, 244]. Myometrial 
maturation continues into adulthood. Notably, mechanisms that control myometrial 
development are not well understood. Estrogen seems to play a role in regulating the 
development of circular myometrium [123]. Tamoxifen-treated neonatal mice 
                                                 
 Reprinted in slight modified form with permission from “TGFBR1 is required for 
mouse myometrial development” by Gao Y, Bayless KJ, Li Q. Mol Endocrinol 2014; 
28:380–394. 
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demonstrate disorganized circular myometrium with reduced laminin expression and 
develop a uterine pathology reminiscent of adenomyosis, which is defined as the 
presence of endometrium and uterine glands within myometrium [123]. However, mice 
treated with estradiol develop intact but hypertrophied muscle layers [123]. Additionally, 
wingless/integrase-1 (WNT)/ catenin signaling pathway is known to regulate mouse 
uterine development [124-127]. Wnt-7a mutant female mice develop abnormal oviduct 
and uterus, and smooth muscle defects were observed in the uterus [124, 127]. Despite 
this knowledge, mechanisms that control the development of morphologically and 
functionally normal myometrium remain to be elucidated.  
 
Transforming growth factor  (TGF) superfamily signaling regulates essential cellular 
functions and developmental processes [9]. In an earlier study, we generated a 
conditional knockout (cKO) of the TGFβ type 1 receptor (Tgfbr1) using Cre 
recombinase driven by anti-Müllerian hormone receptor type 2 (Amhr2), which is 
expressed in the mesenchymal cells of the oviduct and uterus [179]. The Tgfbr1 cKO 
females are infertile and develop smooth muscle defects in the reproductive tract. 
Disorganized myometrium is a striking phenotype of the uterus [179]. However, the 
timing of myometrial defects during postnatal uterine development and the underlying 
mechanisms are not clear.  
 
TGF ligands are regulators of smooth muscle cell differentiation in vitro [245, 246]. 
However, little is known about the role of TGFβ signaling in uterine smooth muscle cell 
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differentiation in vivo. Since uterine smooth muscle cell differentiation is a critical step 
of myometrial development, it is essential to define smooth muscle differentiation in the 
Tgfbr1 cKO model. Notably, postnatal uterine development involves extensive 
remodeling of extracellular matrix (ECM) [247], which regulates cellular 
behavior/properties such as proliferation, differentiation, and migration [248, 249]. 
TGF signaling regulates ECM production [250, 251]. Of note, basement membranes 
enclosing smooth muscle cells play key roles in regulating the phenotype and function of 
these cells [252, 253]. It has been shown that basement membranes surrounding mouse 
uterine smooth muscle cells contain collagen IV [254].  
 
Therefore, in this study, we tested whether differentiation of uterine smooth muscle cells 
and production of key proteins associated with basement membrane were altered in 
Tgfbr1 cKO uteri during postnatal uterine development. Our studies focused on a critical 
time window of postnatal uterine development (i.e., postnatal days 0-15), during which 
uterus acquires essential configuration. We herein identified an important role of 
TGFBR1 in regulating myometrial configuration and basement membrane component 
synthesis during postnatal uterine development, and provided further mechanistic 
insights into the myometrial defects in Tgfbr1 conditionally ablated uterus.  
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2.2 Materials and methods 
2.2.1 Ethics statement 
Procedures of mouse manipulation were approved by the Institutional Animal Care and 
Use Committee (IACUC) at Texas A&M University. Mice were maintained on a 
C57BL/6/129S6/SvEv genetic background and housed in standard cages under a 12 h 
light/12 h dark cycle with access to food and water ad libitum. All necessary procedures 
were taken to minimize the discomfort, distress, and pain of the mice during experiment. 
 
2.2.2 Construction of Tgfbr1 conditional knockout mice 
Generation of Tgfbr1 cKO mice using a Cre-loxP strategy was described previously 
[179]. The Amhr2cre allele was kindly provided by Dr. Richard Behringer [171]. A 
bacterial lacZ gene was inserted into the Tgfbr1 gene to generate a loss-of-function (i.e., 
a Tgfbr1 null allele). In the Tgfbr1 conditional allele, the exon 3 of Tgfbr1 gene was 
flanked by two loxP sites as described [238]. Genotyping was performed using tail 
DNAs and polymerase chain reaction (PCR) [179]. 
 
2.2.3 Sample collection and processing 
Uterine samples from control and Tgfbr1 cKO mice were collected at postnatal day 0 
(Birth; P0), P3, P5, P10, and P15. Adult uterine samples were collected from 3 month 
old control and Tgfbr1 cKO mice. The samples were processed for histological analysis, 
RNA isolation, X-gal staining, and immunofluorescence. For periodic acid-Schiff 
(PAS)-hematoxylin staining and immunofluorescence, uterine samples were fixed in 
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10% neutral buffered formalin (NBF) (Sigma) immediately after collection. Samples 
were then washed with 70% ethanol before being processed for paraffin embedding. For 
RNA preparation, samples were homogenized in RNA lysis tissue (RLT) buffer 
(Qiagen) and stored at -80C until isolation. Sample processing for X-gal staining was 
described below.  
 
2.2.4 Histological assays 
All samples were processed and embedded using the Histology Laboratory of Veterinary 
Integrative Biosciences at Texas A&M University. Uterine tissues were serially 
sectioned at 5 m and processed for PAS-hematoxylin staining [145]. 
 
2.2.5 RNA isolation, reverse transcription, and quantitative real-time PCR 
Total RNA was isolated from uterine samples using RNeasy Mini Kit (Qiagen) 
according to manufacturer’s instructions. On-column DNase (Qiagen) digestion was 
incorporated into RNA isolation procedure to remove potential genomic DNA 
contamination. RNA concentration and the ratio of the absorbance at 260 nm and 280 
nm were measured using a NanoDrop Spectrophotometer ND 1000 (NanoDrop 
Technologies). Reverse transcription (RT) was carried out using 200 ng total RNA and 
superscript III (Invitrogen) reverse transcriptase to synthesize the first DNA strand. 
Quantitative real-time PCR (qPCR) was performed using a CFX384/CFX Connect Real-
time PCR Detection System (Bio-Rad). The PCR program consisted of 95C for 30s, 40 
cycles of 95C for 5 s, and 60C for 30s. All assays were performed in duplicate using 
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iTaq Universal SYBR Green Supermix (Bio-Rad) and gene specific primers (Table 3). 
Specificity of the amplification was verified by dissociation curve and gel 
electrophoretic analyses. Ribosomal protein L19 (Rpl19) was used as an internal control. 
Relative levels of gene expression were calculated using CT method [255].  
 
Table 3. Primers for quantitative real-time PCR 
 
Name Sequence (5-3) Reference 
Col4a1 Forward CTGGCACAAAAGGGACGAG PrimerBank ID  
 Reverse ACGTGGCCGAGAATTTCACC 33859528a1 
Col4a2 Forward GACCGAGTGCGGTTCAAAG PrimerBank ID  
 Reverse CGCAGGGCACATCCAACTT 556299a1 
Col4a3 Forward CAAAGGCATCAGGGGAATAACT PrimerBank ID  
 Reverse ACCCTTAGATCCGTTGCATCC 145699100c1 
Col4a4 Forward ATGAGGTGCTTTTTCAGATGGAC PrimerBank ID  
 Reverse GGGGCCGCCATACTTCTTG 34328045a1 
Col4a5 Forward AGGCGAAATGGGTATGATGGG PrimerBank ID  
 Reverse CTCCCTTACCGCCCTTTTCTC 26348681a1 
Col4a6 Forward ATCGGATACTCCTTCCTCATGC PrimerBank ID  
 Reverse CCAGGGGAGACTAGGGACTG 13435918a1 
Fn1 Forward GATGTCCGAACAGCTATTTACCA PrimerBank ID  
 Reverse CCTTGCGACTTCAGCCACT 29835174a1 
Lama1 Forward CGGGTCTGTGACGGTAACAGT [256] 
 Reverse GCCATCGATTGCGTGTGAT  
Lama2 Forward GGAAAAAGGACCCGAGATGTACT [256] 
 Reverse TGAGGGTTCCTCACAGGCTG  
Lama3 Forward TCTTGTAGGGTCTGCCCCTG [256] 
 Reverse AGCTCCACCATCCACAGCAC  
Lama4 Forward CAGCTGGACGACTACAACGC [256] 
 Reverse ATGGTCGAGGGCCTGGTTA  
Lama5 Forward CGGATGGGACCTGTGAAGA [256] 
 Reverse GCTCTCCTGTGAAGTTCGGC  
Lamb1 Forward CCACTGGCGACCTTCTCATC [256] 
 Reverse CTGGTTTGTGCAGTCCACATG  
Lamb2 Forward GAACTTCGCTTGGGCCTACTT PrimerBank ID  
 Reverse GGTGGCTGGATAGCAGCTT 31982223a1 
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Table 3. Continued. 
 
Name  Sequence (5-3) Reference 
Lamb3 Forward GGCTGCCTCGAAATTACAACA PrimerBank ID  
 Reverse ACCCTCCATGTCTTGCCAAAG 6678660a1 
Lamc1 Forward AAGTCCTGTCACCTGTGCGAC [256] 
 Reverse CATAGTCTGGCTTTGCCACCA  
Lamc2 Forward CAGACACGGGAGATTGCTACT PrimerBank ID  
 Reverse CCACGTTCCCCAAAGGGAT 19115956a1 
Lamc3 Forward CGGAGCCCTGCATCACAAA PrimerBank ID  
 Reverse AGCAAGGTCGTCCTCAAAGC 6453719a1 
Tagln Forward CGATGGAAACTACCGTGGAGA [257] 
 Reverse TGAAGGCCAATGACGTGCT  
Acta2 Forward GTCCCAGACATCAGGGAGTAA PrimerBank ID  
 Reverse TCGGATACTTCAGCGTCAGGA 6671507a1 
Actg2 Forward CCGCCCTAGACATCAGGGT PrimerBank ID  
 Reverse TCTTCTGGTGCTACTCGAAGC 6752952a1 
Cnn1 Forward GGTGAAACCCCACGACATCTT [257] 
 Reverse TTTGTCTTGGCCATGCTGG  
Myh11 Forward CATCCTGACCCCACGTATCAA [257] 
 Reverse ATCGGAAAAGGCGCTCATAGG  
Des Forward TACACCTGCGAGATTGATGCC [257] 
 Reverse GCGCAATGTTGTCCTGATAGC  
Smtn Forward TCACTACCTTCAGCCATGCCT [257] 
 Reverse GCCATTAGCTGCTTCCACTGT  
Myocd Forward CCAACACCTTGCCCAGTTATC [179] 
 Reverse GGAGCTTGTGCTGCCAAAG  
Tgfb1 Forward CTCCCGTGGCTTCTAGTGC PrimerBank ID  
 Reverse GCCTTAGTTTGGACAGGATCTG 6755775a1 
Tgfb2 Forward TCGACATGGATCAGTTTATGCG PrimerBank ID  
 Reverse CCCTGGTACTGTTGTAGATGGA 6678317a1 
Tgfb3 Forward CAGGCCAGGGTAGTCAGAG [258] 
 Reverse ATTTCCAGCCTAGATCCTGCC  
Pdgfa Forward GAGGAAGCCGAGATACCCC PrimerBank ID  
 Reverse TGCTGTGGATCTGACTTCGAG 6715566a1 
Pdgfb Forward AAGTGTGAGACAATAGTGACCCC PrimerBank ID  
 Reverse CATGGGTGTGCTTAAACTTTCG 6755010a1 
Pdgfc Forward GCCAAAGAACGGGGACTCG PrimerBank ID  
 Reverse AGTGACAACTCTCTCATGCCG 10242385a1 
Pdgfd Forward TACAGTTGCACTCCCAGGAAT PrimerBank ID  
 Reverse CTTCCAGTTGACAGTTCCGCA 27229137a1 
Rpl19 Forward ATGAGTATGCTCAGGCTACAGA PrimerBank ID  
 Reverse GCATTGGCGATTTCATTGGTC 6677773a1 
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2.2.6 X-gal staining 
X-gal staining was conducted as described previously [179]. Briefly, mouse uterine 
samples were fixed in fixation buffer (2% paraformaldehyde, 0.2% glutaraldehyde, and 
0.1 M phosphate pH 7.4) and then rinsed with rinse buffer (0.01% sodium deoxycholate, 
0.02% NP-40, 2 mM MgCl2, and 0.1 M phosphate pH 7.4). The samples were stained for 
16 h at room temperature in staining buffer (5 mM potassium ferricyanide, 5 mM 
potassium ferrocyanide, and 1 mg/ml X-gal dissolved in rinse buffer). After staining, the 
samples were washed with PBS, fixed in 10% NBF, and further processed for paraffin 
embedding and sectioning. At the final step, the sections were deparaffinized, 
rehydrated, and counterstained with fast red (Vector lab). 
 
2.2.7 Immunofluorescence, immunohistochemistry, and immunocytochemistry 
Paraffin-embedded samples were cut into serial sections (5 m), which were 
subsequently deparaffinized in xylene and rehydrated in graded alcohol. The sections 
were boiled in 10 mM citrate buffer (pH 6.0) for 20 min to expose the antigens. After 
antigen retrieval, sections were briefly washed with Tris-buffered saline (TBS) and 
blocked with 3% bovine serum albumin (BSA) for 1h at room temperature. Primary 
antibodies (Table 4) were then added and incubated at 4C overnight. After primary 
antibody incubation, the sections were washed and incubated with Alexa Fluor 488 or 
594 conjugated anti-rabbit/rat/mouse IgG (Invitrogen). The sections were thoroughly 
washed before being mounted with ProLong Gold Antifade Reagent with DAPI 
(Invitrogen). Omission of primary antibodies and replacement of primary antibodies by 
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normal IgGs were used as negative controls. The immunoreactive signals were examined 
and images were captured using IX47 fluorescence microscope with a digital camera 
(Olympus). For immunohistochemistry, an ABC method was used following primary 
antibody incubation as described [179]. The signals were developed and visualized using 
a DAB substrate kit (Vector Labs). Then immunostained sections were counterstained 
with hematoxylin, and mounted with Permount (Fisher). 
 
Table 4. Primary antibodies for immunofluorescence 
 
Name Manufacturer Catalog no. Host Dilution  
ACTA2 Abcam ab5694 Rabbit 1:1000 
ACTA2 Abcam ab76549 Mouse 1:1600 
CNN1 Millipore 04-589 Rabbit 1:500 
Vimentin Cell Signaling 5741 Rabbit 1:200 
Collagen IV Abcam ab19808 Rabbit 1:200 
Laminin Abcam ab11575 Rabbit 1:200 
FN1 Abcam ab23750 Rabbit 1:400 
CD31 Abcam ab28364 Rabbit 1:200 
ACTG2 Abcam ab155308 Rabbit 1:1000 
TAGLN Abcam ab14106 Rabbit 1:1500 
KRT8 DSHB* TROMA-I Rat 1:100 
FOXA2 Abcam ab108422 Rabbit 1:250 
PR Thermo Scientific RB-9017 Rabbit 1:500 
PDGFRA Cell Signaling 3174 Rabbit 1:200 
PDGFRB Cell Signaling 3169 Rabbit 1:200 
Note: * Developmental Studies Hybridoma Bank  
 
Immunocytochemistry was performed using a standard protocol. Briefly, the cells were 
fixed with 4% paraformaldehyde in PBS for 15 min at room temperature and then 
permeabilized with 0.1% Triton X-100 for 15 min. The cells were then washed with 
PBS, blocked with 10% normal goat serum, and incubated with rabbit anti-calponin 1 
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antibody (Millipore) overnight. After washing, the cells were incubated with Alexa Fluor 
594 conjugated anti-rabbit IgG (Invitrogen) for 1 h. The filamentous actin (F-actin) was 
stained with phalloidin conjugated to Alexa-488 (Invitrogen). The nucleus was labeled 
with DAPI using ProLong Gold Antifade Reagent (Invitrogen).  
 
2.2.8 Western blot 
Western blot was performed as described [145]. Briefly, protein lysates (25 µg) were 
resolved on 10% Tris gel (Bio-Rad) and electro-blotted to the PVDF membranes (Bio-
Rad). The membrane was incubated with rabbit anti-platelet-derived growth factor 
(PDGF) AA antibody (1:500; Millipore) and rabbit anti-GAPDH (1:1000; Cell 
Signaling) in 5% BSA. The secondary antibody was horseradish peroxidase (HRP)-
conjugated donkey anti-rabbit (1:10,000 in 5% milk; Jackson ImmunoResearch). 
SuperSignal West Dura Chemiluminescent Substrate (Pierce) was used to detect the 
signals according to the manufacturer’s instruction. Signals were developed using Kodak 
Image Station 4000 mm PRO (Kodak). The band intensity for PDGFAA and GAPDH 
was quantified using ImageJ software (NIH, 1.47v) and expressed as a ratio of the 
intensity of PDGFAA to that of GAPDH to normalize the variation in sample loading. 
 
2.2.9 Mouse uterine smooth muscle cell isolation and culture 
Uterine smooth muscle cell isolation was performed according to previously published 
protocols with slight modifications [119, 259]. Uteri from 2-3 month old adult virgin 
mice were collected and kept in Hank's Buffered Salt Solution (HBSS) (Buffer A; pH 
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7.4) containing penicillin and streptomycin (Gibco; 100 U/ml) and amphotericin B 
(Sigma; 2.5 μg/ml). The uterine horns were washed with buffer A without calcium and 
magnesium (Buffer B) and cut into 2-3 mm pieces and subject to enzymatic digestion at 
37 °C with agitation using buffer B containing 1 mg/mL collagenase type II (Sigma), 
0.15 mg/mL DNase I (Roche), 1 mg/mL BSA (Sigma), 0.1 mg/mL soybean trypsin 
inhibitor (Sigma), and 10% FBS (Gibco). After 30 min incubation, the digestion mixture 
was triturated for 3 min. Equal volume of buffer C (buffer B plus 10% FBS) was added 
to the digestion mixture before passing through a cell strainer. The first digestion 
mixture was discarded to minimize cell debris and damaged cells. The remaining tissues 
were subject to the above incubation-aspiration procedure for five times. The cell 
suspension from each digestion was kept on ice and combined after the digestion 
procedure was completed. The combined mixture was centrifuged at 200 × g for 15 min, 
and the cell pellet was collected and resuspended in phenol red-free Dulbecco's modified 
Eagle's Medium (DMEM; Thermo Scientific) containing 10% FBS, 100 U/mL 
penicillin/streptomycin, 2.5 μg/mL amphotericin B (Sigma), and 25 mM Hepes (Gibco). 
The cells were allowed to an additional attachment step to improve the purity of uterine 
smooth muscle cells as described [119, 259]. Cells were cultured at 37 °C with 5% CO2.   
 
2.2.10 Mouse uterine stromal cell isolation and culture 
Isolation and culture of uterine stromal cells were carried out based on a protocol 
described elsewhere with slight modifications [260, 261]. In brief, uterine horns of adult 
virgin mice were cleaned of fat, opened longitudinally, cut into 3-5 mm pieces, and 
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washed with HBSS without calcium and magnesium containing 100 U/ml 
penicillin/streptomycin (Gibco). The tissues were then incubated in HBSS without 
calcium and magnesium that contained 0.5% trypsin (AMRESCO; 100 U/ml) for 1 h at 4 
°C, followed by two further incubations for 1 h at room temperature and 10 min at 37 
°C. The supernatant was discarded and the tissues were washed with HBSS before 
further digestion using 0.05% collagenase (Sigma) for 45 min at 37 °C. To disperse the 
stromal cells, the digestion mixture was vortexed until the supernatant was turbid. The 
mixture was then passed through a 70-μm cell strainer (BD). Cells were collected by 
centrifugation at 400  g for 10 min and cultured in DMEM-F12 (Lonza) supplemented 
with 10% FBS and 100 U/mL penicillin/streptomycin. The cells were then seeded in 
culture dishes and incubated at 37 °C with 5% CO2. After 90 min incubation, cells were 
washed with HBSS without calcium and magnesium and cultured in DMEM-F12 
supplemented with 10% FBS and 100 U/mL penicillin/streptomycin. 
 
2.2.11 Cell migration assay 
Cell migration analysis was performed using a Boyden chamber assay with slight 
modifications [262]. Selection of the dosage of PDGFAA (20 ng/mL) and PDGFBB (20 
ng/mL) was based on a preliminary dose-response experiment. Briefly, uterine stromal 
cells were trypsinized and re-suspended in serum-free DMEM medium. DMEM with or 
without PDGFAA/PDGFBB was loaded onto the lower well of a 48-well chemotaxis 
chamber (Neuro Probes, Inc). The chamber was fitted with a polycarbonate membrane 
(8-μm pore size) that was coated with 30 µg/mL of collagen I (R&D). Fifty µl of uterine 
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stromal cells (~5×104 cells) was added to the upper assay chamber and incubated for 5 h 
at 37°C with 5% CO2. The membrane was then immersed in 3% glutaraldehyde solution 
(Sigma) for 20 min before being stained with 0.1% Amido Black (Sigma) for 20 min. 
After staining, the cells that adhered to the top layer of the membrane were removed 
using a cotton swab. The membrane was then mounted on a glass slide, imaged, and 
analyzed by densitometry using Quantity One software (Bio-Rad). The mean value of 
the control mice without PDGFs was set to 100% and the results were expressed as the 
percentage of the control for PDGF treatment. 
 
2.2.12 Statistical analyses 
A one-way analysis of variance (ANOVA) was conducted to determine the difference 
among groups. When a significant difference was detected by ANOVA, the difference 
between means was further defined by a post-hoc Dunnett test. Comparison of means 
between two groups was assessed using student t-test. Data represent mean ± standard 
error of the mean (SEM). Statistical significance was defined at P < 0.05. All statistical 
analyses were performed using SPSS software (Statistical Package for the Social 
Sciences; Version 21). 
 
2.3 Results 
2.3.1 TGFBR1 is required for normal myometrial development 
Our previous studies demonstrated that TGFBR1 is essential for female reproductive 
tract integrity and function [179]. Conditional knockout of Tgfbr1 in the female 
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reproductive tract using Amhr2-Cre leads to prominent smooth muscle defects in the 
oviduct and uterus with full penetrance [179]. To define a time line of the myometrial 
defects during postnatal uterine development, we first performed PAS staining to 
compare myometrial development in Tgfbr1 cKO and control mice at P0, P3, P5, P10, 
and P15 (Appendix A-1). At P3, three layers of the uterus (i.e., inner, middle and outer 
layers) were evident by PAS-hematoxylin staining in the controls (Appendix A-1C) 
[121]. Highly organized smooth muscle layers were formed developmentally in the 
controls (Appendix A-1A, C, E, G, and I), but not in the Tgfbr1 cKO mice (Appendix A-
1B, D, F, H, and J). 
 
To better visualize the myometrial compartment and monitor its development, we 
performed immunofluorescence using an antibody directed against calponin 1 (CNN1) 
(Figure 3). At birth (P0), the CNN1 signal intensity was low in the uteri of control and 
Tgfbr1 cKO mice (Figure 3A and B). At P3, the prospective circular myometrial layer in 
the control mice was clearly identified using the anti-CNN1 antibody (Figure 3C). In 
contrast, CNN1-positive cells were dispersed and an intact circular myometrial layer was 
not found in the Tgfbr1 cKO mice (Figure 3D). At P5, a pronounced disruption of the 
circular myometrial layer was evident in the Tgfbr1 cKO mice compared to control mice 
(Figure 3E and F). Further development of the longitudinal myometrium characterized 
by smooth muscle bundles was visualized at P10 and P15 in the wild type uterus (Figure 
3G and I), which is in contrast to the age-matched Tgfbr1 cKO mice whose longitudinal 
layers were thinner and not well organized into bundles in certain regions at these time 
 36 
 
points (Figure 3H and J). Immunofluorescence using additional smooth muscle markers 
including smooth muscle alpha actin (ACTA2), smooth muscle gamma actin (ACTG2), 
and transgelin (TAGLN) confirmed these findings (data not shown). These data indicate 
that TGFBR1 is indispensable for proper myometrial development in mice.  
 
 
Figure 3. Myometrial defects in Tgfbr1 cKO mice during early uterine development. 
Localization of CNN1 (Green) at P0 (A and B), P3 (C and D), P5 (E and F), P10 (G and 
H), and P15 (I and J) in control and Tgfbr1 cKO mice. Representative images are shown 
for each time point (n = 3). Note that at birth (P0), the CNN1 signal intensity was low in 
the uteri of control and Tgfbr1 cKO mice. CNN1-positive cells emerged at P3, and 
defects in uterine smooth muscle cell formation occurred as early as P3 examined. CM, 
circular smooth muscle layer; LM, longitudinal smooth muscle layer. Scale bar = 20 m. 
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Figure 4. Adenogenesis in Tgfbr1 cKO mice. (A-D) Localization of KRT8 (Green) and 
ACTA2 (Red) in the uteri of control and Tgfbr1 cKO mice at P5 (A and B) and P15 (C 
and D). Note that KRT8 was restricted to uterine luminal epithelium and surface 
epithelium before uterine gland formation at P5, and the presence of KRT8-positive 
uterine glands in the disrupted myometrial layers of Tgfbr1 cKO mice at P15. (E and F) 
Localization of FOXA2 (Red) and KRT8 (Green) in the uteri of control and Tgfbr1 cKO 
mice at P15. (G and H) Localization of PR (Red) and ACTA2 (Green) in the uteri of 
control and Tgfbr1 cKO mice at P15. Representative images are shown for each group (n 
= 3). LE, luminal epithelium; GE, glandular epithelium; CM, circular smooth muscle 
layer. Scale bar = 20 m (A, B, E, and F) and 50 m (C, D, G, and H). 
 
2.3.2 Uterine glands develop in the Tgfbr1 Amhr2-Cre conditional knockout mice  
In contrast to the marked disruption of myometrial development in the Tgfbr1 cKO 
mice, development of uterine glands seemed to be initiated and progressed similarly as 
control mice during early postnatal development (Figure 4). Immunofluorescence 
analysis of cytokeratin 8 (KRT8), an epithelial marker, revealed that KRT8 was 
restricted to uterine luminal epithelium and surface epithelium in both control and 
Tgfbr1 cKO mice at P5 before uterine gland formation (Figure 4A and B). At P15, 
uterine adenogenesis occurred in both control and Tgfbr1 cKO mice (Figure 4C and D). 
FOXA2, a regulator of uterine adenogenesis, was expressed in the glandular epithelium 
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of both Tgfbr1 cKO and controls (Figure 4E and F). Because progesterone signaling is a 
key determinant of uterine adenogenesis [263], we examined progesterone receptor (PR) 
expression and found that the distribution pattern of PR was comparable between control 
and Tgfbr1 cKO uteri during early uterine development (Figure 4G and H), which is in 
agreement with uterine gland formation in these mice during the early developmental 
period. However, in contrast to controls where no uterine glands within the myometrium 
(Figure 4C). KRT8-positive uterine glands were detected within the myometrial lesions 
in Tgfbr1 cKO mice (Figure 4D). Thus, despite the fact that adenogenesis was normally 
initiated in the Tgfbr1 cKO uteri, further development of uterine glands seemed to be 
hampered, at least partially due to the incorrect spatial distribution predisposed by the 
failure of myometrial formation. Collectively, these findings lend support to a cellular 
basis for the adenomyosis observed in adult Tgfbr1 cKO uteri, where morphologically 
normal/abnormal uterine glands were intermingled within the myometrium (Appendix 
A-2).  
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Figure 5. TGFβ isoforms and TGFBR1 are expressed in the mouse uterus during its 
early development. (A-C) Transcript levels of Tgfb1 (A), Tgfb2 (B), and Tgfb3 (C) 
during postnatal uterine development at P0 (n = 5), P3 (n = 4), P5 (n = 3), P10 (n = 4), 
and P15 (n = 4). Data are mean  SEM. *P < 0.05 vs. P0. (D) Schematic representation 
of Tgfbr1lacZ allele and X-gal staining. (E) Gross anatomy of uteri of control (Ctrl) and 
Tgfbr1flox/lacZ mice after X-gal staining. Note the dark blue staining in the Tgfbr1flox/lacZ 
uterus and no discernible staining in uteri of control mice. (F-H) X-gal staining of 
uterine sections from P3 (F), P5 (G), and P15 (H) mice harboring a Tgfbr1lacZ allele. n = 
3-5 for each time point. Dotted red lines outline the myometrium. The dotted yellow line 
marks the boundary between circular and longitudinal smooth muscle layers. Note that 
the signals for X-gal staining were increased with the progression of uterine smooth 
muscle cell differentiation. Ep, epithelium; M, myometrium; LM, longitudinal smooth 
muscle; CM, circular smooth muscle. Scale bar (20 m) is representatively shown in (F). 
Sections in panels F-H were counterstained with nuclear fast red. 
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2.3.3 TGFβ ligand/receptor components are expressed during postnatal uterine 
development 
To examine the potential involvement of TGF isoforms (TGFB1-3)/receptor signaling, 
we analyzed their expression during postnatal uterine development. Tgfb1 and Tgfb3 
transcript levels increased after birth and reached a plateau at P5 (Figure 5A and C). In 
contrast, expression of Tgfb2 mRNA did not increase, but remained constant from P0 to 
P5 and declined at P15 (Figure 5B). To determine the localization of TGFBR1, the type 
1 receptor for TGFB1-3, in the mouse uterus during early myometrial development, we 
performed X-gal staining of uterine samples containing a Tgfbr1 LacZ allele (i.e., 
Tgfbr1lacZ) in which expression of -galactosidase is driven by the Tgfbr1 promoter 
(Figure 5D-H). While control uterine horns showed no discernible staining, the uteri 
from Tgfbr1flox/lacZ mice had strong blue staining (Figure 5E). Histological analysis 
further revealed that the X-gal staining was more strongly localized to the myometrial 
cells, with increasing staining intensity from P3 to P15 in this compartment (Figure 5F-
H). Taken together, these results provide evidence that TGF signaling may regulate 
myometrial development through paracrine and/or autocrine actions. 
 
2.3.4 Uterine smooth muscle cells express lineage markers in Tgfbr1 cKO mice 
In vitro studies suggest that TGF signaling regulates smooth muscle gene expression 
[264-266]. However, it is not clear whether TGF signaling is required for uterine 
smooth muscle cell differentiation in vivo. Therefore, we sought to determine whether 
deletion of Tgfbr1 in uterine mesenchymal cells affects differentiation of smooth muscle 
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cells during early uterine development. As a first step, we analyzed the expression of a 
variety of well-established smooth muscle marker genes including Acta2, Actg2, Cnn1, 
Tagln, desmin (Des), smoothelin (Smtn), and smooth-muscle myosin heavy chain 
(Myh11), as well as a critical regulator of smooth muscle gene expression, myocardin 
(Myocd) [267] during postnatal development in wild type mice using qPCR (Figure 6). 
Consistent with the initiation and progression of smooth muscle cell differentiation 
during postnatal uterine development, mRNA levels for all the examined smooth muscle 
marker genes were increased and reached the highest levels at P10 or P15 (Figure 6A-
G). Interestingly, the transcript abundance for Myocd was increased about 2-fold and 
reached a plateau at P3 (Figure 6H).  
 
Next, we examined whether conditional deletion of Tgfbr1 altered the expression of the 
aforementioned smooth muscle genes. In line with the protein expression of CNN1 
(Figure 3), the transcript levels of Cnn1 were not distinguishable between control and 
Tgfbr1 cKO uteri at P5 (Figure 6I). Except for a decline in Tagln transcript levels, the 
abundance of Acta2, Des, Smtn, Myh11, Actg2, and Myocd mRNAs remained 
comparable between Tgfbr1 cKO and control mice (Figure 6I). Similar changes in the 
expression of examined genes were also found at P10 when expression of the majority of 
the smooth muscle markers reached the highest abundance (data not shown). These 
results suggest that myometrial defects in Tgfbr1 cKO mice may not directly arise from 
an intrinsic deficiency in uterine smooth muscle cell differentiation.  
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Figure 6. Developmental dynamics of mRNA abundance for smooth muscle 
markers/regulator during postnatal uterine development and the effect of conditional 
ablation of Tgfbr1 on expression of smooth muscle genes and F-actin cytoskeleton of 
uterine smooth muscle cells. Transcript levels of Acta2 (A), Actg2 (B), Cnn1 (C), Tagln 
(D), Des (E), Smtn (F), Myh11 (G), and Myocd (H) in the wild type uterus during 
postnatal uterine development at P0 (n = 5), P3 (n = 4), P5 (n = 3), P10 (n = 4), and P15 
(n = 4). (I) Relative levels of expression of mRNAs for smooth muscle genes/regulator 
in the uteri of control (n = 5) and Tgfbr1 cKO mice (n = 5) at P5. Note that mRNA levels 
for smooth muscle marker genes reached the highest levels at P10 or P15, and no 
significant difference was detected between control and Tgfbr1 cKO mice except for 
Tagln, which showed about 30% reduction. Data are mean  SEM. *P < 0.05 vs. P0 (A-
H) or corresponding controls (I). (J-M) F-actin (Green) and CNN1 staining (Red) of 
control (J and K) and Tgfbr1 cKO (L and M) smooth muscle cells. The dotted yellow 
line marks smooth muscle cells. Scale bar = 20 m. 
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Figure 7. Temporal changes in abundances of collagen IV and laminin mRNAs during 
early postnatal uterine development. Transcript levels of Col4a1 (A), Col4a2 (B), 
Col4a3 (C), Col4a4 (D), Col4a5 (E), Col4a6 (F), Lama2 (G), Lama3 (H), Lama4 (I), 
Lama5 (J), Lamb1 (K), Lamb2 (L), Lamb3 (M), Lamc1 (N), Lamc2 (O), and Lamc3 (P) 
in wild type uteri during postnatal development at P0 (n = 5), P3 (n = 4), P5 (n = 3), P10 
(n = 4), and P15 (n = 4). Note that collagen IV genes were developmentally regulated 
and expression plateaued at P5 (Col4a1 and Col4a2), P10 (Col4a4, Col4a5, and 
Col4a6), or P15 (Col4a3), while expression of mRNAs for the majority of laminin genes 
peaked at P10 and P15. Data are mean  SEM. *P < 0.05 vs. P0.  
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To further characterize the cellular properties of the uterine smooth muscle cells in vitro, 
we isolated and cultured mouse uterine myocytes. We were able to enrich uterine 
smooth muscle cells from wild type control mice (Figure 6J and K). In the controls, F-
actin was clearly stained and distributed in an organized pattern (Figure 6J), and the 
identity of smooth muscle cells was confirmed using immunofluorescence staining of 
CNN1 (Figure 6K), as well as ACTA2 (data not shown). However, the same smooth 
muscle cell isolation protocol did not efficiently enrich for myocytes from Tgfbr1 cKO 
mice (Figure 6L and M), potentially due to the disruption of the myometrium within the 
uterus (i.e., myometrial cells were intermingled with endometrium). The myocytes from 
Tgfbr1 cKO mice seemed to have clearly stained F-actin fibers when cultured in vitro 
(Figure 6L).  
     
2.3.5 Production of ECM proteins associated with the basement membrane is 
impaired in uteri in which Tgfbr1 is conditionally ablated 
The ECM components undergo constant remodeling (i.e., synthesis, deposition, and 
degradation), which is implicated in normal development and diseases [268, 269]. To 
determine the expression pattern of ECM components associated with the basement 
membrane zone, we analyzed the expression of type IV collagen (Col4a1, Col4a2, 
Col4a3, Col4a4, Col4a5, and Col4a6), laminin (Lama1, Lama2, Lama3, Lama4, Lama5, 
Lamb1, Lamb2, Lamb3, Lamc1, Lamc2, and Lamc3), and fibronectin (Fn1) genes. We 
found that expression of collagen IV genes in the mouse uterus was developmentally up-
regulated after birth and plateaued at P5 (Col4a1 and Col4a2; Figure 7A and B), P10 
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(Col4a4, Col4a5, and Col4a6; Figure 7D-F), or P15 (Col4a3; Figure 7C). The laminin 
genes were also regulated during development and the transcript levels of the majority of 
laminin genes (Lama3, Lama4, Lama5, Lamb2, Lamb3, Lamc1, Lamc2) peaked at P10 
(Figure 7H-J and L-O) and P15 (Lama2 and Lamc3; Figure 7G and P). Lama1 mRNA 
levels were close to the detection limit and thus Lama1 was excluded from this analysis. 
In contrast, no significant changes in Lamb1 and Fn1 were found at the examined time 
points (Figure 7K and Appendix A-3A).  
 
Table 5. Relative expression of mRNAs for collagen IV genes in uteri of control and 
Tgfbr1 cKO mice at P5 and P10 
 
 P5 Ctrl (n = 5) P5 cKO (n = 5) P10 Ctrl (n = 5) P10 cKO (n = 3) 
Gene Mean  SEM Mean  SEM Mean  SEM Mean  SEM 
Col4a1 1.00  0.03 0.81  0.04* 1.03  0.13 0.98  0.16 
Col4a2 1.12  0.30 1.22  0.17 1.00  0.05 0.73  0.19 
Col4a3 1.01  0.06 0.90  0.13 1.01  0.06 0.64  0.13* 
Col4a4 1.01  0.08 0.82  0.03* 1.00  0.03 0.70  0.03* 
Col4a5 1.01  0.05 0.74  0.07* 1.01  0.08 0.66  0.05* 
Col4a6 1.01  0.05 1.03  0.04 1.01  0.06 0.85  0.02 
*P < 0.05 vs. age-matched controls 
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Figure 8. Conditional ablation of Tgfbr1 reduces expression of collagen IV in the mouse 
uterus during early development. (A-F) Subcellular localization of collagen IV (Green; 
A and B), ACTA2 (Red; C and D), and collagen IV and ACTA2 (E and F) in uteri of 
control mice at P5. (G-L) Subcellular localization of collagen IV (Green; G and H), 
ACTA2 (Red; I and J), and collagen IV and ACTA2 (K and L) in uteri of Tgfbr1 cKO 
mice at P5. Note the diminished immunofluorescence signals for collagen IV in the 
smooth muscle cells of Tgfbr1 cKO mice (G-L) compared with control mice (A-F). 
Representative images are shown for each group (n = 3). The yellow dotted lines 
indicate that the circular smooth muscle layers developed at P5. CM, circular smooth 
muscle layer; COL4, collagen IV. Scale bar = 20 m. 
 
Based on the fact that postnatal uterine development involves extensive ECM 
remodeling and the role of TGF in this process [270, 271], we hypothesized that the 
production of type IV collagen chains and other ECM components associated with the 
basement membrane is impaired in the Tgfbr1 cKO uteri. To test this hypothesis, we 
performed qPCR to compare the transcript levels of genes encoding collagen IV, 
laminin, and fibronectin between control and Tgfbr1 cKO mice at P5 and P10, two 
 47 
 
critical time points of myometrial formation. Our results showed a reduction in 
expression of Col4a1, Col4a4, and Col4a5 mRNAs in the Tgfbr1 cKO mice compared 
with control mice at P5 (Table 5). Analysis of P10 samples revealed down-regulation of 
Col4a3, Col4a4, and Col4a5 transcripts in mice with conditionally deleted Tgfbr1 (Table 
5). To further examine the subcellular localization and potential alterations in collagen 
IV protein in Tgfbr1 cKO mice, we performed immunofluorescence analyses and found 
that collagen IV was strongly associated with microvessels (Figure 8A, B, E, F, G, H, K, 
and L). A signal for collagen IV was also detected in the newly formed circular smooth 
muscle layers in the control mice at P5 (Figure 8A-F). However, immunofluorescence 
signals for collagen IV in the disrupted uterine smooth muscle layers of the Tgfbr1 cKO 
mice were diminished (Figure 8G-L). Meanwhile, we observed a change in the 
distribution of endometrial blood vessels in the Tgfbr1 cKO uteri compared with 
controls using CD31/PECAM-1 to label endothelial cells within the endometrium 
(Appendix A-4). 
 
A significant reduction in transcript levels for laminin genes was not detected in the 
Tgfbr1 cKO mice at P5 or P10 with the exception of Lama2 and Lamc2 for which the 
mRNA levels were reduced at P10 (data not shown). Since the qPCR was performed 
using whole uterine tissues that could potentially mask the cell-specific changes in 
expression of laminin, we further examined laminin protein localization in the uterine 
tissue sections. Immunofluorescence analyses demonstrated that the predominant sites of 
laminin expression were microvessels and uterine smooth muscle layers (Appendix A-
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5A, B, E, F, G, H, K, and L). Well-organized circular myometrial layers with abundant 
laminin expression were found in control mice (Appendix A-5A-F). However, disruption 
of the uterine smooth muscle layer formation was accompanied by a reduction in laminin 
signals in the uterine smooth muscle cells of Tgfbr1 cKO mice (Appendix A-5G-L). In 
contrast to the dysregulation of collagen IV and laminin, the expression of FN1 was not 
different between control and Tgfbr1 cKO uteri (Appendix A-3B-F). These data suggest 
that the compromised synthesis of basement membrane components resulting from 
conditional deletion of Tgfbr1 may disrupt basement membrane deposition and interfere 
with myometrial organization/formation. 
 
2.3.6 Altered platelet-derived growth factor (PDGF) expression in Tgfbr1 cKO uteri 
and the role in uterine stromal cell migration 
PDGFs are well-established migratory factors [272, 273]. In the Tgfbr1 cKO uteri, we 
found greater expression of mRNAs for Pdgfa and Pdgfb during early uterine 
developmental stages (Figure 9A). Western blot analysis demonstrated the increased 
expression of PDGFAA in the Tgfbr1 cKO uteri (Figure 9B). To explore the implication 
of the increased PDGFs in the uterus of Tgfbr1 cKO mice, we first analyzed the PDGF 
receptor (PDGFRA and PDGFRB) localization during postnatal uterine development. 
We found that PDGFRA (Figure 9C-F) and PDGFRB (Figure 9G-J) were predominantly 
localized to uterine stromal cells, with no expression in the epithelium. In the 
myometrial compartment, PDGFRA signals were close to background level, while 
PDGFRB expression was low, but detectable (Figure 9C-J).  
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Figure 9. Altered PDGF expression in Tgfbr1 cKO uteri and its role in uterine stromal 
cell migration. (A) Relative expression of mRNAs for Pdgfa, Pdgfb, Pdgfc, and Pdgfd in 
the uteri of control and Tgfbr1 cKO mice at P5 (n = 5 per group). (B) Western blot 
analysis of PDGFAA protein in control and Tgfbr1 cKO mice. Representative images 
are depicted in the upper panel and the lower panel shows the relative intensity of 
PDGFAA, which is expressed as a ratio of the density of PDGFAA to that of GAPDH (n 
=3 per group). (C-F) Subcellular localization of PDGFRA in uteri of control (C and D) 
and Tgfbr1 cKO mice (E and F) at P5. (G-J) Subcellular localization of PDGFRB in 
uteri of control (G and H) and Tgfbr1 cKO mice (I and J) at P5. Representative images 
(C-J) are shown for each group (n =3). Note the PDGFRA and PDGFRB signals were 
strongly present in the stromal cells but absent from the uterine epithelium. LE, luminal 
epithelium; St, stroma; Myo, myometrium. Scale bar (20 m) is representatively denoted 
in (C). (K) Primary uterine stromal cells express vimentin (VIM). Isolated uterine 
stromal cells were cultured for 24 h and stained with anti-vimentin antibody. Scale bar = 
20 m. (L) PDGFAA and PDGFBB induce uterine stromal cell migration in control and 
Tgfbr1 cKO mice. Representative images of cells in the Boyden chamber assay are 
depicted in the upper panel, and the lower panel shows the quantification data from three 
independent assays. Data are mean  SEM. *P < 0.05 vs. corresponding controls. 
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Based on the cellular distribution of PDGF receptors in the uterus, we postulated that 
PDGFs regulate/control cell migration during postnatal uterine development. To test this 
hypothesis, we isolated mouse primary uterine stromal cells, which are positive for 
vimentin (Figure 9K). Using a Boyden chamber assay, we found that PDGFAA and 
PDGFBB (20 ng/mL) induced uterine stromal cell migration (P < 0.05) in both control 
and Tgfbr1 cKO mice to similar levels, and the ability of stromal cells to migrate was not 
altered in the Tgfbr1 cKO mice (Figure 9L). Hence, elevated PDGFs could potentially 
enhance uterine stromal cell migration via paracrine action in the Tgfbr1 cKO mice 
during postnatal uterine development.  
 
2.4 Discussion 
2.4.1 Role of TGFBR1 in myometrial development and pathology 
Accumulating evidence indicates an obligatory role for TGF superfamily signaling in 
female reproduction [142, 274]. TGF superfamily members and signaling components 
including TGFs [153, 154], activin [167], myostatin [168] and TGFBRs and SMADs 
[152, 154] are present in the myometrium. TGFs modulate the rate of DNA synthesis 
of human myometrial smooth muscle cells [154], while activin and myostatin inhibit 
human myometrial cell growth/proliferation [167, 168]. These studies provide 
circumstantial evidence that TGF superfamily signaling is involved in the development 
and/or function of the myometrium. However, the in vivo function of TGF 
ligands/receptors and their associated signaling cascades in the myometrium are poorly 
defined. 
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The essential role of TGFβ signaling in the female reproductive tract was demonstrated 
in the Tgfbr1 conditional knockout mouse model [179]. Conditional deletion of Tgfbr1 
in the mesenchymal compartments of the female reproductive tract using Amhr2-Cre 
renders the mice infertile [179]. The Tgfbr1 cKO mice are viable and the infertility is not 
attributed to ovarian dysfunction, but caused by the development of oviductal 
diverticulum [179]. Remarkably, these mice develop smooth muscle defects in the 
oviduct and uterus [179]. By focusing on a critical time window of postnatal uterine 
development, we found that uterine smooth muscle defects in Tgfbr1 cKO mice occurred 
during early development. The developmental expression of TGF isoforms and the 
localization of TGFBR1 in the myometrial cells provided further evidence in support of 
the involvement of TGF signaling in the myometrium. Although the myometrial 
defects and alteration in basement membrane components were primarily caused by loss 
of TGFBR1 in uterine smooth muscle cells, our results did not rule out the potential 
contribution of the Amhr2-Cre expression in endometrial stromal cells to the observed 
phenotype/molecular alterations.  
 
In contrast to the myometrial disruption, development of uterine glands seemed to be 
initiated and progressed normally during early uterine development in the Tgfbr1 cKO 
mice. However, in adult mice, the Tgfbr1 cKO myometrium showed reduced continuity 
and the presence of endometrium and uterine glands within the myometrium, resembling 
adenomyosis observed in mice exposed to tamoxifen, an estrogen receptor antagonist, 
during the neonatal period [123, 275]. The incorrect spatial localization of uterine glands 
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during adenogenesis owing to the myometrial lesions supports the emerging concept that 
myometrial defects may contribute to the etiology of uterine adenomyosis [123]. Of 
note, aged Tgfbr1 cKO mice had glandular defects in the uterus [179], which was 
potentially secondary to the disruption of uterine smooth muscle development and/or 
altered uterine mesenchymal-epithelial interactions. 
  
2.4.2 Implications of TGFβ signaling in uterine smooth muscle differentiation, 
basement membrane protein synthesis, and myometrial integrity 
In mice, uterine mesenchymal cells remain randomly oriented and undifferentiated until 
after birth. Between birth and P3, myometrial layers are differentiated from the 
mesenchyme [121], marking the beginning of myometrial development. Formation of 
the circular myometrial layer precedes that of the longitudinal layer and is evident by P5. 
The essential structure of myometrium is well developed by P15 [121]. TGFβ signaling 
regulates the in vivo differentiation of vascular smooth muscle [276]. To determine 
whether conditional deletion of Tgfbr1 affected uterine smooth muscle cell 
differentiation, we examined transcript levels of a number of known smooth muscle 
genes and regulators in Tgfbr1 cKO uteri. Surprisingly, mRNA levels of most examined 
genes were comparable between control and Tgfbr1 cKO uteri at P5 and P10, two 
critical time points of myometrial development. However, expression of Tagln mRNA 
was reduced (~30%) in the Tgfbr1 cKO mice at P5, but not at P15 (data not shown). 
TAGLN and ACTG2 seem to be more specific markers for smooth muscle than ACTA2, 
which is also expressed in non-smooth muscle cells and myofibroblast-like cells [277, 
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278]. However, Tagln knockout mice are viable and fertile [279]. Although the role of 
TAGLN remains to be identified, it is tempting to speculate that reduced expression of 
TAGLN is associated with delayed/reduced myofibroblast differentiation. Furthermore, 
the cytoskeleton of uterine smooth muscle cells seemed to be intact in the Tgfbr1 cKO 
mice. Altogether, our data suggest that the myometrial defects may not directly arise 
from an intrinsic deficiency in uterine smooth muscle cell differentiation.   
 
ECM components undergo constant remodeling and regulate smooth muscle 
development by influencing essential cellular funcitons [268, 269]. Collagen IV and 
laminin are critically invloved in smooth muscle cell differentiation [280, 281]. 
Regulation of smooth muscle cell phenotype by basement membrane components has 
been reported [252, 282]. Based on those findings, we asked whether the myometrial 
defects in Tgfbr1 cKO mice were associated with dysregulation of ECM proteins, 
especially basement membrane components.  
 
Vascular smooth muscle cells are enclosed with basement membranes that regulate their 
functions [252, 253]. However, the formation, regulation, and function of basement 
membranes of uterine smooth muscle cells within the myometrium are not well defined, 
despite evidence that mouse uterine smooth muscle cells express several collagen genes 
[254]. The finding of reduced synthesis of collagen IV and laminin in Tgfbr1 cKO mice 
during early uterine development suggests a potential defect in basement membrane 
deposition. Of note, loss of Smad4 causes altered basement membrane deposition during 
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early development in mice [283]. Our findings support the notion that smooth muscle 
cells regulate the development of their basement membranes [284]. On the other hand, 
the altered production of key basement membrane proteins may profoundly affect 
uterine smooth muscle differentiation (e.g., timing) and myometrial structural 
development. Understanding the dynamics of synthesis of basement membrane proteins 
and their role in regulating cell fate and function during postnatal uterine development 
remains a future goal.    
 
2.4.3 Platelet-derived growth factors as potential regulators of uterine development 
Further efforts toward exploring mechanisms underlying the developmental failure of 
the myometrium in Tgfbr1 cKO mice identified PDGF signaling as a potentially 
important contributing factor. PDGFs are known migratory regulators for cells including 
endometrial stromal cells and vascular smooth muscle cells [272, 273]. The increased 
expression of PDGFs in the Tgfbr1 cKO mice is a manifestation of a potentially indirect 
effect of loss of TGFBR1 in the uterus because induction of PDGFs by TGF1 in vitro 
was reported [285]. Interestingly, PDGFAA and PDGFBB promoted the migration of 
uterine stromal cells from both control and Tgfbr1 cKO mice, consistent with the 
expression of PDGF receptors by these cells. Although stromal cells isolated from 
Tgfbr1 cKO and control mice migrated identically in response to PDGFs, increases in 
PDGFs could potentially enhance cell migration via paracrine action in vivo. Indeed, 
both Pdgfa and Pdgfb mRNAs were expressed by uterine stromal cells and smooth 
muscle cells (Gao Y, unpublished results). Furthermore, the altered abundance of 
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PDGFs may also affect the uterine vasculature, as PDGFs are known to regulate 
angiogenesis and vascular stabilization [286, 287]. Collectively, the deficiency in 
production of extracellular matrix components and abnormal uterine cell migration may 
contribute to the disrupted myometrial formation in Tgfbr1 cKO mice during postnatal 
uterine development.  
 
In summary, this study identified an important role for TGFBR1 in regulating 
myometrial configuration and synthesis of basement membrane components during early 
postnatal uterine development, highlighting TGFBR1 as an essential regulator of 
myometrial development.   
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3. CONSTITUTIVE ACTIVATION OF TRANSFORMING GROWTH FACTOR 
BETA RECEPTOR 1 IN THE MOUSE UTERUS IMPAIRS UTERINE 
MORPHOLOGY AND FUNCTION* 
 
3.1 Introduction 
Transforming growth factor beta (TGFΒ) superfamily signaling plays a pleiotropic role 
in fundamental cellular and developmental processes [288]. TGFB superfamily ligands 
[e.g., TGFBs, activins, and bone morphogenetic proteins (BMPs)] interact with their 
membrane bound type 2 and type 1 receptors to form a heteromeric complex. 
Subsequent phosphorylation of the type 1 receptor at the glycine and serine (GS) 
domains by the constitutively active type 2 receptor activates receptor-regulated 
intracellular SMAD proteins, which modulate gene transcription in concert with the 
common SMAD (i.e., SMAD4), co-activators, and co-repressors [44, 289].  
 
TGFB superfamily signaling activity is precisely controlled under normal physiological 
conditions. Multiple regulatory factors including ligand traps (e.g., follistatin), ligand 
activators (e.g., tenascin-X), inhibitory SMADs (i.e., SMAD6 and SMAD7), and 
agonistic/antagonistic pathways may cooperate to govern the normal activity and 
function of this pathway [289-295]. Accumulating evidence indicates that TGFB 
                                                 
* Partially reprinted with permission from “Constitutive activation of transforming 
growth factor beta receptor 1 in the mouse uterus impairs uterine morphology and 
function” by Gao Y, Duran S, Lydon JP, DeMayo FJ, Burghardt RC, et al. Biol Reprod 
2015; 92(2):34. 
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superfamily members are key regulators of female reproduction, including, but not 
limited to, follicular development, ovulation, oocyte-cumulus cell communications, 
uterine decidualization, and conceptus development [138-149, 179]. 
 
TGFB ligands (i.e., TGFB1-3) are founding members of the TGFB superfamily. TGFBs 
signal via TGFB receptor 1 (TGFBR1/ALK5) and receptor 2 (TGFBR2) and 
downstream SMAD2/3 proteins. Identification of the in vivo function of TGFB signaling 
in the uterus remains a challenging puzzle, partially because of the potential redundancy 
of the ligands [232, 233] and the lack of appropriate animal models. TGFB signaling 
components including TGFB ligands, receptors, and SMADs are expressed in the mouse 
and human myometrium and regulate DNA synthesis in human myometrial cells [152-
154].  In the rat uterus, myometrial expression of TGFB1 and TGFB3 is increased from 
mid-gestation, with TGFB3 strongly localized to the circular myometrial layer at late 
pregnancy [155].  Interestingly, TGFB3 levels are higher in human leiomyoma cells 
versus myometrial cells, and TGFB3 is expected to promote leiomyoma development 
via stimulating cell growth and fibrogenic process [212]. By taking advantage of a 
conditional knockout approach, we have shown that ablation of Tgfbr1 in the female 
reproductive tract using anti-Müllerian hormone receptor type 2 (Amhr2)-Cre 
recombinase leads to smooth muscle defects and reproductive failure [179, 242], 
suggesting an essential role for TGFB signaling in myometrial development.  
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That TGFB signaling is finely tuned argues for the need to use both loss-of-function and 
gain-of-function approaches to fully understand its physiologic and pathologic roles. 
Constitutively active receptors can be used to investigate the impact of sustained 
elevation of a signaling pathway on the pathogenesis of diseases. To our knowledge, 
mouse models with enhanced TGFB signaling in the female reproductive tract are 
lacking. Notably, overactivation of TGFB signaling is linked to the development of 
diseases, including cancer [296-298]. Therefore, in the current study, we created a 
mouse model harboring a constitutively active TGFBR1 in the uterus whose expression 
is conditionally induced by the progesterone receptor (Pgr)-Cre. Over-activation of 
TGFB signaling causes infertility and striking phenotypic alterations in the uteri of these 
mice. Our results highlight the importance of a precisely controlled TGFB signaling 
system in establishing a uterine microenvironment conducive to normal development 
and function.  
 
3.2 Materials and methods 
3.2.1 Animals and treatment 
All protocols using laboratory mice were approved by the Institutional Animal Care and 
Use Committee (IACUC) at Texas A&M University. Mice were maintained on a mixed 
C57BL/6/129SvEv genetic background. Mice were exposed to a 12h dark/12h light 
cycle with access to food and water ad libitum during the entire experimental period. 
The Pgr-Cre mice were created as described [299]. Mice harboring constitutively active 
TGFBR1 were generated previously, where strategies including genetic modifications 
 59 
 
were described [300]. Briefly, constitutive activation of the receptor in the absence of 
ligand results from three missense mutations: T204D that constitutively activates the 
TGFBR1 kinase [46] and L193A/P194A that prevent binding of the TGFBR1 inhibitor, 
FKBP12 [301]. Mice harboring the Rosa26-LacZ allele [Gt(ROSA)26Sortm1Sor/J] [302] 
were purchased from the Jackson Laboratory and used as a reporter for Pgr-Cre 
expression. Fertility testing was performed by breeding the control and experimental 
female mice with proven fertile males for a period of 3-months. Superovulation of 
immature females was performed as described previously [145]. Analysis of uterine 
decidualization was conducted as reported [179, 303]. Briefly, ovariectomized mice 
received subcutaneous injections of estradiol (E2; 100 ng/mouse for 3 days; Sigma). The 
mice were rested for 2 days and then treated with E2 (6.7 ng/mouse) and progesterone 
(P4; 1.0 mg/mouse; Sigma). After 2 days of injection, one uterine horn was traumatized 
using a burred needle, while the other served as unstimulated control. Two days after the 
decidual stimulus, mice were sacrificed and uterine samples collected. The uterine horns 
were weighed and total RNA was prepared for real-time PCR analysis as described 
below. Alkaline phosphatase staining was performed to examine uterine stromal cell 
differentiation as described previously [240].  
 
3.2.2 Mouse breeding, genotyping, and DNA recombination analysis 
To generate mice with conditionally activated TGFBR1 (TGFBR1CA), mice containing a 
latent constitutively active TGFBR1 were bred with Pgr-Cre mice. Genomic DNA was 
isolated from mouse tails using NaOH buffer. Genotyping and DNA recombination 
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analyses of the TGFBR1CA allele were carried out using polymerase chain reaction 
(PCR) [300, 304, 305]. Primers used for genotyping of Pgr-Cre have been described 
elsewhere [147]. PCR products were separated on 1% agarose gels containing ethidium 
bromide and digital images captured using a VWR Gel Imager.  
 
3.2.3 Histological analysis 
Uterine and ovarian samples were collected from control and experimental mice at 
defined ages (1 week or 1-3 months) and fixed in neutral buffered formalin. The 
histology core facility of the Department of Veterinary Integrative Biosciences at Texas 
A&M University was used for sample processing and embedding. Paraffin sections (5 
m) were serially generated, and hematoxylin and eosin (HE) staining was conducted 
using a standard protocol. After staining, slides were mounted and examined with a 
microscope and images were captured using a digital camera (DP25; Olympus) with 
cellSens® Digital Imaging Software.  
 
3.2.4 X-gal staining 
Uteri from mice harboring Rosa26-LacZ and Pgr-Cre were collected and fixed as 
described [179]. The samples were washed and stained using staining buffer containing 
1 mg/ml X-gal, 5 mM potassium ferricyanide, and 5 mM potassium ferrocyanide 
(Sigma). Samples were then sequentially processed for post-fixation, paraffin 
embedding, sectioning, and fast red counterstaining [179].  
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3.2.5 Human uterine smooth muscle cell line culture and treatment 
A well-characterized human myometrial cell line, PHM1-41 [306-308] was used to 
determine the effect of TGFB ligands on alpha smooth muscle actin (ACTA2) expression 
in uterine smooth muscle cells. Briefly, PHM1-41 cells were cultured in DMEM 
supplemented with 10% fetal bovine serum (FBS), penicillin-streptomycin, and 0.1 
mg/ml G418 sulfate. Prior to the experiment, G418 was omitted. The cells were serum-
starved overnight before treatment. For the SMAD2/3 phosphorylation study, the cells 
were treated with TGFB1 (2.5 ng/ml; R&D) and collected after 40 min of treatment. The 
cells were then processed for immunofluorescence as described [242]. Briefly, the cells 
were fixed with 4% paraformaldehyde in cold PBS for 15 min and permeabilized with 
0.1% Triton X-100 for another 15 min. The cells were then blocked with 10% normal 
goat serum and incubated with rabbit anti-SMAD2/3 antibody (Cell Signaling; 1:100) 
overnight at 4C. After washing, the cells were incubated with Alexa Fluor 594 
conjugated anti-rabbit IgG (Invitrogen) for 1 h. The nuclei were labeled with DAPI 
using ProLong Gold Antifade Reagent (Invitrogen). For gene expression analysis, the 
cells were treated with 2.5 ng/ml of TGFB1 (R&D Systems), TGFB2 (HumanZyme), 
and TGFB3 (HumanZyme). Selection of the dosage for TGFBs was based on a pilot 
experiment. Cells were collected after 20 h of treatment and processed for RNA isolation 
and real-time PCR analysis.  
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3.2.6 Immunofluorescence microscopy 
Immunofluorescence microscopy was performed using serial paraffin sections [179]. 
Antigen retrieval was performed to expose the hidden antigenic sites by boiling the 
sections for 20 min in 10 mM citrate buffer (pH 6.0) using a microwave oven. Following 
antigen retrieval, the sections were blocked with 5% bovine serum albumin (BSA; 
Sigma) and incubated with the following primary antibodies overnight at 4C in a humid 
box: mouse anti-ACTA2 (Abcam; 1:2,000), rat anti-cytokeratin 8 (KRT8) 
(Developmental Studies Hybridoma Bank; 1:100), rabbit anti-vimentin (VIM) (Cell 
Signaling; 1:200), and goat anti-3-beta-hydroxysteroid dehydrogenase (HSD3B) (Santa 
Cruz; 1:1000). The slides were next incubated with secondary antibodies conjugated 
with Alexa Fluor 488 or 594 (Invitrogen) at room temperature for 1 h and the sections 
were mounted using ProLong Gold Slowfade media with DAPI. The slides were 
examined using an IX73 microscope (Olympus) interfaced with an XM10 CCD camera 
and cellSens® Digital Imaging Software. To determine the background levels of the 
above assays, controls where primary antibodies were replaced by isotype-matched IgGs 
purified from the same species as the primary antibodies were included.  
     
3.2.7 Western blot 
Protein lysates were prepared using radioimmunoprecipitation assay (RIPA) buffer [145] 
containing proteinase and phosphatase inhibitors (Roche) and quantified using a 
bicinchoninic acid (BCA) Protein Assay Kit (Thermo Scientific). Protein samples (~30 
g) were separated on 10% Tris gel, transferred to polyvinylidene difluoride (PVDF) 
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membranes (Bio-Rad), and incubated overnight at 4°C with the following primary 
antibodies: mouse anti- hemagglutinin (HA) (Santa Cruz; 1: 200), rabbit anti-phospho-
SMAD2 (Millipore; 1:500); rabbit anti-SMAD2 (Cell Signaling; 1:1000), and mouse 
anti-beta actin (ACTB) (Sigma; 1:50000). Then, the membranes were washed and 
further incubated with horseradish peroxidase (HRP)-conjugated donkey anti-rabbit 
antibody (Jackson ImmunoResearch; 1:20,000) at room temperature for 1 h. The signals 
were developed with Immobilon Western Chemiluminescent HRP Substrate (Millipore) 
and scanned using a Kodak Image Station 4000 mm PRO. ACTB was used as an internal 
control. ImageJ (NIH, 1.47v) was used for western blot quantification, where the 
intensity of target bands was normalized to that of ACTB to correct for variations in 
sample loading. 
 
3.2.8 RNA isolation and real-time PCR 
Mouse uterine tissues were homogenized and total RNA was isolated using an RNeasy 
Mini Kit (Qiagen) according to the manufacturer’s instruction. On column DNase 
digestion was performed during the procedure to eliminate potential DNA 
contamination. Total RNA was quantified using a NanoDrop Spectrophotometer ND 
1000 (NanoDrop Technologies). Two hundred ng of total RNA were reverse transcribed 
to generate complementary DNA (cDNA) [242]. Then real-time PCR was performed 
using CFX Connect Real-time PCR Detection System (Bio-Rad) and iTaq Universal 
SYBR Green Supermix (Bio-Rad) [242].  
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Quantification of matrix metalloproteinase 9 (Mmp9), Acta2, calponin 1(Cnn1), desmin 
(Des), smoothelin (Smtn), transgelin (Tagln), smooth muscle actin gamma (Actg2), 
myosin heavy chain 11(Myh11), Bmp2, follistatin (Fst), and ACTA2 was conducted as 
described [242, 309, 310]. Primers used for serine (or cysteine) peptidase inhibitor clade 
E member 1 (Serpine1), connective tissue growth factor (Ctgf), Bmp2, Fst and TGFB-
induced factor homeobox 1 (TGIF1) are listed below: Serpine1 (Forward: 5’- 
TTCAGCCCTTGCTTGCCTC-3’, Reverse: 5’- ACACTTTTACTCCGAAGTCGGT-3’; 
ID# 6679373a1), Ctgf (Forward: 5’- GGGCCTCTTCTGCGATTTC-3’, Reverse: 5’- 
ATCCAGGCAAGTGCATTGGTA-3’; ID#6753878a1), Bmp2 (Forward: 5’-
GGGACCCGCTGTCTTCTAGT-3’, Reverse: 5’-TCAACTCAAATTCGCTGAGGAC-
3; ID# 6680794a1), Fst (Forward: 5’-TGCTGCTACTCTGCCAGTTC-3’, Reverse: 5’-
GTGCTGCAACACTCTTCCTTG-3’; ID# 6679867a1), and TGIF1 (Forward: 5’- 
GGGATCAGTTTTGGCTCGTCC-3’, Reverse: 5’- 
GCAGTCACAGTGGTATGGCAG-3’). Serpine1, Ctgf, Bmp2, and Fst primers were 
obtained from PrimerBank [311]. Rpl19 [242] and RPLP0/36B4 [119] were used as 
internal controls for the respective mouse and human gene expression analyses. The 
assays were performed in duplicate for each biological replicate. Relative levels of gene 
expression were calculated as described [255]. 
 
3.2.9 Statistical analysis 
The statistical analysis was performed using Statistical Package for the Social Sciences 
(SPSS; Version 21). A one-way analysis of variance (ANOVA) was applied to 
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determine the differences in means among treatment groups, followed by a Bonferroni 
post-hoc test. Comparisons of mean values from two groups were made using the 
student’s t-test. Data are presented as mean ± standard error of the mean (SEM). 
Significance was defined when a P value is less than 0.05. 
 
 
Figure 10. Generation of mice containing a constitutively active TGFBR1 gene in the 
uterus. (A) Schematic representation of the latent constitutively active TGFBR1 allele. 
Pt, Hprt promoter; HA, hemagglutinin tag; CAG, composite constitutive CAG (human 
cytomegalovirus enhancer and chicken beta actin); Hprt, hypoxanthine-guanine 
phosphoribosyl transferase. (B) The TGFBR1CA Lox/Lox mice were bred with Pgr-Cre 
mice to produce control (TGFBR1CA Lox/Lox; Ctrl) and experimental mice (TGFBR1CA 
Lox/Lox; Pgr-Cre; TGFBR1 Pgr-Cre CA). (C) Illustration of genotyping PCR of female 
pups. Lanes 1-3 represent WT, TGFBR1CA Lox/Lox, and TGFBR1CA Lox/Lox; Pgr-Cre, 
respectively.  
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Figure 11. Constitutively active TGFBR1 enhances TGFB signaling in the mouse 
uterus. (A) DNA recombination. Rec, recombination. (B) TGFBR1CA mRNA levels were 
significantly higher in mice containing a constitutively active TGFBR1. Real-time PCR 
was performed using uteri samples from control (Ctrl) and TGFBR1CA Lox/Lox; Pgr-Cre 
(CA) mice at the age of 1 week and 1 month (n = 4). Note that the primers amplify the 
transgene. (C and D) Western blot analysis of TGFBR1-HA fusion protein, phospho-
SMAD2, and SMAD2 in the uteri of control and TGFBR1CA Lox/Lox; Pgr-Cre mice. Note 
that upper panels show the representative western blot images, while the lower panels 
depict the results of quantification for TGFBR1CA (C) and phospho-SMAD2 (D). Each 
lane represents an independent sample. Uterine samples were collected from mice at the 
age of 6 wk (n = 3-5). (E-G) Increased mRNA expression of Serpine1, Ctgf, and Mmp9 
in the uteri of TGFBR1CA Lox/Lox; Pgr-Cre mice compared with controls. Uterine samples 
were collected from mice at 1 wk of age (n = 4). Data are mean  SEM. *P < 0.05 versus 
controls.  
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3.3 Results 
3.3.1 Generation of mice harboring a constitutively active TGFBR1 in the uterus 
To create a gain-of-function model of TGFBR1 in the mouse uterus, we took advantage 
of a latent constitutively active TGFBR1 allele (TGFBR1CA), where a constitutively 
active TGFBR1 was knocked into the hypoxanthine guanine phosphoribosyl transferase 
(Hprt) locus [300] (Figure 10A). We created mice harboring the TGFBR1CA whose 
expression was conditionally induced by Pgr-Cre recombinase (TGFBR1 Pgr-Cre CA) 
(Figure 10B and C). Pgr-Cre is expressed in the uterus [312] and has been extensively 
utilized as a Cre deletor for genes expressed in the uterus [104, 147, 313, 314]. By 
crossing the Pgr-Cre mice with Rosa26 LacZ reporter mice [302], we verified the 
expression of Pgr-Cre in the uterus (data not shown). Pgr-Cre recombinase can remove 
the “stop” sequence of the constitutively active TGFBR1 allele in the uterus, leading to 
the expression of the constitutively active TGFBR1.  
 
To validate this model, we first determined whether TGFBR1CA allele could be 
recombined at the genomic DNA level. Using specific recombination primers for 
TGFBR1CA [304] and uterine DNA isolated from control and TGFBR1 Pgr-Cre CA 
mice, a band with the expected size was detected in the uterus of TGFBR1 Pgr-Cre CA 
mice, but not control mice (Figure 11A). Next, we performed quantitative real-time PCR 
and demonstrated that TGFBR1CA mRNA was significantly greater in uteri of TGFBR1 
Pgr-Cre CA mice compared with control mice (Figure 11B). Using an antibody directed 
against HA, we further showed that TGFBR1CA-HA fusion protein expression was 
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induced in the TGFBR1 Pgr-Cre CA uterus (Figure 11C) and correlated with increased 
abundance of phospho-SMAD2, an indicator of TGFB signaling activity (Figure 11D). 
Consistent with enhanced TGFB signaling activity in the uterus, mRNA levels of TGFB 
targets including Serpine1 (Figure 11E), Ctgf (Figure 11F), and Mmp9 (Figure 11G) 
were up-regulated in uteri of TGFBR1 Pgr-Cre CA mice at the age of 1 week, a critical 
time-point for early postnatal uterine development. Therefore, we created a mouse model 
with enhanced TGFB signaling in the uterus. 
 
Table 6. Fertility tests for TGFBR1 Pgr-Cre CA and control mice 
 
Genotype n Pups/litter Litter/month 
TGFBR1CA Lox/Lox 4 10.0  0.5 1.0  0.0 
TGFBR1CA Lox/Lox; Pgr-Cre 6 0 0 
 * The fertility test was conducted during a 3-month period. Data are mean ± SEM. 
 
3.3.2 Mice harboring a constitutively active TGFBR1 in the uterus are infertile and 
develop myometrial and glandular defects 
TGFBR1 Pgr-Cre CA mice were sterile during a 3-month fertility test period compared 
with control mice (Table 6). To determine the potential causes of the infertility and 
investigate the effect of activation of TGFB signaling in the uterus, we first performed 
immunofluorescence microscopy using antibodies against ACTA2, a smooth muscle cell 
marker. Hypermuscled uteri were identified in sexually immature TGFBR1 Pgr-Cre CA 
mice (Figure 12D and F) compared with control mice (Figure 12A and C). 
Immunofluorescence examination of keratin 8 (KRT8), an epithelial marker, was 
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performed to evaluate the integrity of uterine epithelia in the TGFBR1 overactivation 
mice. Interestingly, a marked reduction in uterine glands was detected in TGFBR1CA 
Lox/Lox; Pgr-Cre mice (Figure 12B, C, E, and F). 
 
To determine whether these morphological alterations were preserved in older mice, 
circular and longitudinal layers were examined in adult mice at the age of 2-3 months 
(Figure 12G-R and Appendix A-6). While organized myometrial layers were evident in 
control mice (Figure 12G and J and Appendix A-6A and B), an increased thickness of 
the myometrium and a disorientation of the inner circular layer of myometrium with 
gaps between smooth muscle bundles was observed in the TGFBR1 Pgr-Cre CA mice 
(Figure 12H and K and Appendix A-6C and D). Longitudinal orientation of muscle 
structures could also be found within the circular layer region in TGFBR1 Pgr-Cre CA 
mice (Figure 12I and L). In contrast to the circular myometrium, defects in the 
longitudinal layer were less pronounced at the examined time stages (Figure 12M, N, P, 
and Q). Altogether, these results showed that constitutive activation of TGFBR1 in the 
mouse uterus promoted the development of hypermuscled uteri with a disorganized 
myometrial structure.      
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Figure 12. Constitutively active TGFBR1 in the mouse uterus causes myometrial and 
glandular defects. (A-F) Immunofluorescence detection of ACTA2 (red) and KRT8 
(green) in uterine samples from control and TGFBR1CA Lox/Lox; Pgr-Cre mice. Note the 
increased thickness of  the myometrium (D and F), reduced uterine glands (E and F), and 
myofibroblast-like cells within stroma (D and F) in TGFBR1 Pgr-Cre CA mice 
compared with age-matched control mice (A-C). Uterine samples from 1 month old 
control and TGFBR1CA Lox/Lox; Pgr-Cre mice (n = 3) were analyzed and representative 
images are shown. (G-R) Immunofluorescence of ACTA2 in the uteri of control and 
TGFBR1CA Lox/Lox; Pgr-Cre mice. Note the disorganized smooth muscle cell orientation 
(green; H and K) and the presence of muscle structures with longitudinal orientation 
within the circular myometrial layer region (I and L) compared with controls (G and J). 
Less pronounced alterations of longitudinal muscle structure was found in TGFBR1CA 
Lox/Lox; Pgr-Cre mice (N and Q) versus control mice (M and P). (O and R) 
Representative negative controls where the primary antibody for ACTA2 was replaced 
with mouse IgG. LE, luminal epithelium; GE, glandular epithelium; Myo, myometrium; 
Neg, negative controls. The scale bars is representatively shown in (A) and equals 100 
µm (A-F) and 25 µm (G-R).  
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Figure 13. Co-localization of ACTA2 and vimentin in the endometrium. (A-H) 
Representative images of immunofluorescence for ACTA2 and vimentin using uterine 
samples from control and TGFBR1CA Lox/Lox; Pgr-Cre mice. Note the presence of 
abundant ACTA2-positive cells (green) in the stroma (B), and those cells did not express 
vimentin (red; F and H). (G) and (H) are higher power images for (E) and (F), 
respectively. DAPI (blue) was used to counterstain the nucleus. VIM, vimentin. Scale 
bar = 20 µm (A-F) and 10 µm (G and H). 
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We next examined whether development of the endometrium was altered in TGFBR1 
Pgr-Cre CA mice. In contrast to control mice (Figure 13A and E), the endometrium of 
the TGFBR1CA Lox/Lox; Pgr-Cre mice contained abundant ACTA2-positive cells (Figure 
13B and F), suggesting a potential increase in the myofibroblast-like cells. These 
ACTA2-positive cells were negative for vimentin as demonstrated by double 
immunofluorescence of ACTA2 and vimentin (Figure 13F and H), the latter of which 
was predominantly expressed in normal uterine fibroblasts (Figure 13C, E, and G). 
Therefore, over-activation of TGFB signaling appears to promote myofibroblast-like cell 
differentiation in the endometrium of the uterus. 
 
3.3.3 Increased smooth muscle gene expression in uteri of mice with constitutively 
active TGFBR1 
Along with the hypermuscled uterine phenotype, the expression of a battery of smooth 
muscle genes including Acta2, Cnn1, Des, Smtn, Tagln, Actg2, and Myh11 was up-
regulated in uteri of TGFBR1 Pgr-Cre CA mice at 1 wk of age compared with age-
matched controls (Figure 14A). To independently test whether TGFB signaling 
enhanced expression of smooth muscle genes in myometrial cells in vitro, we utilized a 
well-characterized uterine smooth muscle cell line, PHM1. TGFB1 activated SMAD2/3 
in PHM1 cells, evidenced by the nuclear accumulation of SMAD2/3 in TGFB1-treated 
cells versus vehicle control cells (VEHL; Figure 14B). The addition of multiple TGFB 
isoforms stimulated the expression of ACTA2 (Figure 14C). TGIF1, a known TGFB-
induced gene in human myometrial cells [270], was included as a positive control 
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(Figure 14D). These results suggest that TGFB signaling promotes expression of smooth 
muscle genes in uterine myometrial cells. 
 
 
Figure 14. TGFB signaling promotes expression of uterine smooth muscle genes. (A) 
Increased expression of smooth muscle genes in uteri of TGFBR1 Pgr-Cre CA mice at 1 
week of age compared with age-matched controls (n = 4). Data are mean  SEM. *P < 
0.05 versus corresponding controls. The dotted line marks gene expression levels for 
controls mice. (B) TGFB1 activated SMAD2/3 in PHM1 cells. DAPI was used to 
counterstain the nuclei of PHM1 cells. Images are representative for 
immunofluorescence staining from two independent culture experiments. (C and D) 
TGFB ligands stimulated ACTA2 and TGIF1 expression in PHM1 cells. Data are mean  
SEM from three independent cell culture experiments. Bars without a common letter are 
significantly different (P < 0.05). 
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3.3.4 Dysregulation of TGFB signaling alters uterine fibroblast function  
To define the timing of the glandular defects during postnatal uterine development, we 
performed immunofluorescence analysis of KRT8 to compare adenogenesis in TGFBR1 
Pgr-Cre CA and control mice on postnatal days (D) 5, 7, and 15. Uterine glands were 
formed normally in control uteri on D5, 7 and 15, which is consistent with previous 
studies [315, 316]. In contrast, formation of uterine glands were impaired in the uteri of 
TGFBR1 Pgr-Cre CA mice (Appendix A-7), suggesting that glandular defects occur 
during the initiation of adenogenesis.  
 
Adenogenesis involves epithelial cell proliferation and epithelial-mesenchymal 
interactions which are regulated by growth factors such as WNT signaling and cell-
extracellular matrix interactions [132, 315, 317]. Immunohistochemical analysis of Ki67 
expression indicated that adenogenic defects occurred in spite of the unimpeded 
proliferation of uterine luminal epithelial cells at D7 (Appendix A-8). Analysis of genes 
encoding the WNT signaling pathway components at various developmental time-points 
using quantitative real-time PCR revealed that the majority of WNT signaling 
components were comparable between control and TGFBR1 Pgr-Cre CA uteri at D7 
except for Wnt11 (Appendix A-9). However, Wnt11 Pgr-Cre cKO mice have normal 
uterine adenogenesis [317]. Dysregulation of Wnt4, Wnt7a, Wnt16 and catenin beta 1 
(Ctnnb1) was found at D15 and/or D31 in the TGFBR1 Pgr-Cre CA uteri compared with 
control uteri (Appendix A-9).  
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TGFB signaling is known to induce tissue fibrosis by regulating extracellular matrix 
deposition and integrin expression [318, 319]. As expected, we observed increased 
expression of genes associated with fibrosis such as Ctgf, the extracellular matrix gene 
laminin alpha 1 (Lama1) and integrin alpha 1 (Itga1), in TGFBR1 Pgr-Cre CA uteri at 
D7 and collagen type I alpha 1 (Col1a1) and Itgb1 at D15 and D31 (Appendix A-10) 
[318-321]. To test whether TGFB signaling regulates the expression of these genes in 
vitro, we isolated primary stromal cells which were serum starved and treated with 
TGFB1. TGFB1 treatment induced the expression of pro-fibrotic genes and smooth 
muscle genes (Appendix A-11), suggesting that enhanced TGFB signaling may hamper 
adenogenesis by promoting fibrotic changes of endometrial stroma. 
  
3.3.5 Impaired uterine decidualization in mice with constitutively active TGFBR1 
The significantly altered endometrial phenotype of TGFBR1 Pgr-Cre CA mice pointed 
to potential defects in uterine function. To test this possibility, we assessed the ability of 
the uterus to undergo decidualization, a process wherein endometrial stromal cells 
differentiate into decidual cells to support implanted blastocysts during pregnancy. An 
artificial decidualization experiment was performed using a well-established protocol 
(Figure 15A) to determine whether constitutively active TGFBR1 in the mouse uterus 
compromised the uterine decidual response. Two days after the deciduagenic stimulus, 
the ratio of the weight of the stimulated and unstimulated uterine horns of the TGFBR1 
Pgr-Cre CA mice was significantly lower than that of control mice (Figure 15B-D), 
suggesting decidualization defects in mice with enhanced TGFB signaling in the uterus. 
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Further histological analysis and results of an alkaline phosphatase (AP) staining assay 
(Figure 15E-J) demonstrated impaired decidualization and uterine stromal cell 
differentiation in the TGFBR1 Pgr-Cre CA mice, as evidenced by low levels of AP 
staining (Figure 15J), compared with controls (Figure 15G).         
 
To further explore the molecular mechanism responsible for the defective 
decidualization, we assessed the ability of a deciduagenic stimulus to induce the 
expression of critical regulators of uterine decidualization in the TGFBR1 Pgr-Cre CA 
uteri by examining whether expression and induction of Bmp2 and Fst were altered. 
Interestingly, we found that the deciduagenic stimulus failed to induce Bmp2 and Fst 
expression in the TGFBR1 Pgr-Cre CA mice, whereas expression of those genes 
increased following the deciduagenic stimulation in uteri of control mice (Figure 15K 
and L). Moreover, a marked reduction in Bmp2 transcript abundance occurred in the 
decidualized horns of TGFBR1 Pgr-Cre CA mice compared with controls (Figure 15K). 
No significant differences in Fst mRNA levels between decidualized horns of TGFBR1 
Pgr-Cre CA and control mice were detected (Figure 15L). Therefore, enhanced TGFB 
signaling compromises uterine decidualization. 
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Figure 15. Constitutively active TGFBR1 in the uterus impairs uterine decidualization. 
(A) Illustration of the artificial decidualization procedure. OVX, ovariectomy. (B and C) 
Gross morphology of control (B) and TGFBR1 Pgr-Cre CA (C) uteri collected 2 days 
after decidual stimulation. DH, decidualized uterine horn; CH, control uterine horn that 
was not stimulated. (D) Ratio of wet uterine weight between stimulated and unstimulated 
uterine horns of control and TGFBR1 Pgr-Cre CA mice (n = 4-5). (E-J) Histological 
analysis and alkaline phosphatase (AP) staining of uterine tissues from TGFBR1 Pgr-
Cre CA and control mice. Note the strong AP signals in the decidualized horns of 
control mice (G) versus those of TGFBR1 Pgr-Cre CA mice (J). The scale bar is 
representatively depicted in panel (E) and equals 100 µm (E-J). (K and L) Expression of 
Bmp2 and Fst in TGFBR1 Pgr-Cre CA and control uteri during artificial decidualization. 
Note that Bmp2 and Fst transcripts were upregulated by decidual stimulus in control 
mice, but not TGFBR1 Pgr-Cre CA mice. In the decidualized uterine horns, significantly 
lower Bmp2 mRNA levels were detected in the TGFBR1 Pgr-Cre CA mice compared 
with controls (n = 3-4). Ns, not significant. Data are mean  SEM. *P < 0.05. 
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Figure 16. Ovarian pathology of TGFBR1CA Lox/Lox; Pgr-Cre mice. (A-D) Intact smooth 
muscle structure of the oviduct in TGFBR1CA Lox/Lox; Pgr-Cre mice. Immunofluorescence 
of ACTA2 (red) using oviduct collected from 2 month old control (A and B) and 
TGFBR1CA Lox/Lox; Pgr-Cre mice (C and D). (E-H) Hemorrhagic cystic structure in the 
ovary of TGFBR1CA Lox/Lox; Pgr-Cre mice. (G) and (H; dotted yellow line) demonstrate 
the different cystic structures in the same ovary. (I-P) TGFBR1CA Lox/Lox; Pgr-Cre mice 
contained abnormal luteinized structures (K and L; dotted yellow line and yellow arrow 
heads) that were positive for HSD3B (red) (O and P; yellow arrow heads). HSD3B was 
localized mainly to the corpus luteum (yellow arrow heads), but not granulosa cells 
within an adjacent follicle in the control mice (M and N). ACTA2 (green) was used to 
mark the outer theca layer of follicles. DAPI (blue) was used to counterstain the nucleus. 
Ct, cystic structure; CL, corpus luteum; AF, antral follicle. Scale bar = 100 m (A-D and 
H), 200 m (E-G, I, and K), and 50 m (J, L, and M-P). 
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3.3.6 Ovarian defects in mice harboring a constitutively active TGFBR1 
Because Pgr-Cre is also expressed in the oviduct and preovulatory follicles in the ovary 
after the gonadotropin surge, the histology of the oviduct and ovaries was analyzed to 
determine the effects of over-activation of TGFBR1 in these tissues. The histological 
structure of the oviduct of TGFBR1 Pgr-Cre CA mice was comparable to controls, as 
demonstrated by immunofluorescence staining of ACTA2 (Figure 16A-D). However, 
histological studies of the ovary showed that three of eight TGFBR1 Pgr-Cre CA mice 
developed cystic structures filled with blood (Figure 16F-H). In contrast, none of the 
control mice developed that pathology (Figure 16E). Further analysis of mice at 2-3 
months of age showed the presence of abnormal luteinized structures within the ovary of 
the TGFBR1 transgenic mice versus control mice (Figure 16I-L). These structures were 
positive for HSD3B (Figure 16O and P), which was localized to corpora lutea, but not 
ovarian granulosa cells in the control mice (Figure 16M and N). To evaluate the 
ovulatory potential of mice containing a constitutively active TGFBR1, we performed a 
superovulation experiment and demonstrated that immature TGFBR1 Pgr-Cre CA mice 
ovulated a similar number of oocytes as controls in response to exogenous gonadotropin 
injection (39.3  5.9 vs. 40.0  3.9 oocytes/mouse; n = 3-4; P > 0.05). These results 
collectively suggest that over-activation of TGFB signaling profoundly affects ovarian 
cell differentiation and/or function although the ovulation potential in prepubertal mice 
is not altered.  
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3.4 Discussion 
In mice, Müllerian duct formation starts from the specification of coelomic epithelial 
cells that express LIM homeobox protein 1 (Lim1) at embryonic day E11.75 [120]. 
Subsequent invagination of coelomic epithelium into the mesonephros and elongation of 
the duct to the urogenital sinus are completed by E13.5 [120].  The Müllerian duct 
further develops into the female reproductive tract including oviduct, uterus, cervix, and 
the upper part of vagina. The uterus contains simple epithelium and supporting 
mesenchyme at birth, and gradually acquires basic myometrial structures by D15 [121, 
244]. The role of TGFB signaling in myometrial development was revealed in our early 
studies using a Tgfbr1 conditional knockout mouse model. We showed that conditional 
deletion of TGFBR1 in the female reproductive tract disrupts the formation of uterine 
smooth muscle layers [179, 242]. The current study was aimed at developing a gain-of-
function model to achieve further insight into the roles of TGFB signaling in uterine 
development and function.  
 
The role of TGFB superfamily signaling has been identified in many reproductive 
processes using a functional genomics approach. However, the majority of currently 
available mouse models were generated to induce loss-of-function of genes encoding the 
components of TGFB signaling pathway [145, 179, 322-324]. It is noteworthy that over-
activation of TGFB signaling has been associated with diseases including fibrosis, 
Marfan syndrome, and late stage cancers [296-298]. Because TGFB signaling is fine-
tuned and controls homeostatic cellular processes in a highly contextual manner [325], 
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the use of loss-of-function and gain-of-function mouse models is complementary and 
beneficial to a more comprehensive understanding of TGFB signaling in both 
physiological and pathological conditions. Until now, there have been no available 
mouse models with over-activation of TGFB signaling in the female reproductive tract. 
Several strategies have been utilized to develop mouse models with over-activation of 
TGFB signaling. Targeting inhibitors of TGFB signaling such as inhibitory SMADs 
(SMAD6 and SMAD7) [326] and fibrillin [296] can enhance TGFB signaling activity. 
Transgenic mice expressing TGFB1 or having a constitutively active TGFBR1 driven by 
a fibroblast-specific promoter have been reported [327, 328]. By utilizing a latent 
conditional constitutively active TGFBR1 allele [300, 304] and Pgr-Cre, we created a 
mouse model containing a constitutively active TGFBR1 in the uterus. To our 
knowledge, this is the first mouse model with over-activation of TGFB signaling in the 
uterus.  
 
The most striking phenotype of the TGFBR1 Pgr-Cre CA mice is the development of 
hypermuscled uteri, supporting a clear role for TGFB signaling in uterine smooth muscle 
biology. The role of TGFB signaling in smooth muscle cell differentiation and function 
has been unambiguously demonstrated in vascular smooth muscle cells [246, 276, 329, 
330]. While TGFB signaling promotes gene expression in smooth muscle cells and 
formation of smooth muscle in the TGFBR1 gain-of-function model, our studies using 
Tgfbr1 conditional knockout mice [242] suggested that TGFBR1 may not be required for 
the lineage commitment of uterine smooth muscle cells because loss of TGFBR1 allows 
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continued expression of smooth muscle genes in myometrial cells. It is conceivable that 
compensatory mechanisms operate in the absence of TGFB signaling in the TGFBR1 
loss-of-function model. As direct in vitro evidence that TGFB signaling regulates 
smooth muscle gene expression in myometrial cells, we herein demonstrated that TGFB 
signaling activated SMAD2/3 and induced ACTA2 expression in human uterine smooth 
muscle cells. This result suggests a common regulatory mechanism in response to TGFB 
signaling in uterine smooth muscle cells. TGFB signaling induces the differentiation of 
mesenchymal stem cells into smooth muscle cells [331]. It is tempting to speculate that 
enhanced TGFB signaling resulting from constitutively active TGFBR1 may cause 
endometrial stem cell differentiation. Recent evidence suggests the existence of stromal 
stem/progenitor cells in the mouse endometrium, although the properties of these cells 
are incompletely defined [329, 332]. Thus, it remains to be determined whether 
enhanced TGFB signaling affects endometrial stem/progenitor cell differentiation and 
promotes smooth muscle cell formation.  
 
TGFB signaling is involved in myofibroblast differentiation [333]. Myofibroblasts are 
cells that differentiate from quiescent fibroblasts in response to a number of stimuli 
including injury. They are characterized by development of contractile machinery 
induced by changes in the composition and mechanical properties of the extracellular 
matrix [334]. Myofibroblasts express ACTA2 and can be 
differentiated/transdifferentiated from several potential precursor cells including local 
fibroblasts, epithelial cells, and blood-borne cells [335]. Myofibroblasts are generally 
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absent in most tissues, but their differentiation can be induced during tissue repair [336]. 
Human decidual stromal cells resemble myofibroblasts and express ACTA2 [337]. The 
presence, origin, and role of myofibroblasts in the mouse uterus are poorly understood. 
TGFB signaling is a key regulator of myofibroblast differentiation in other systems 
[338]. Supporting a role for TGFB signaling in uterine myofibroblast differentiation, we 
found that overactivation of TGFB signaling led to the differentiation of myofibroblast-
like cells in mouse endometrium, accompanied by an increased expression of smooth 
muscle genes. These ACTA2 positive cells could also potentially be smooth muscle cells 
migrating from the disorganized myometrium of the TGFBR1 Pgr-Cre CA mice. 
Furthermore, our results showed that TGFBR1 Pgr-Cre CA mice had a compromised 
decidualization ability, coincident with uterine morphological aberrations. Uterine gland 
development supports decidualization [339]. It is not known whether reduced uterine 
glands in the TGFBR1 Pgr-Cre CA mice affect decidualization induced by an artificial 
stimulus. The potential contribution of myofibroblast-like cells to the observed 
decidualization defects also awaits elucidation.  
 
Uterine glands are essential for fertility and pregnancy in multiple species of females 
including rodents [132]. Mouse uterine glands develop postnatally. The mechanisms 
underlying uterine gland development are not well understood although recent studies 
using mouse models have identified a few important genes in this developmental process 
such as forkhead box A2 (Foxa2), Wnt4, Wnt5a, Wnt7a, and cadherin 1 (Cdh1) [124, 
127, 133-137]. Elegant studies have utilized progestin treatment to disrupt uterine gland 
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development and fertility in both sheep and mouse models [131, 263]. Likewise, the 
synthetic estrogen, diethylstilbestrol (DES), can also block adenogenesis when 
administered within an appropriate time-frame during postnatal uterine development 
[317]. The exact mechanisms of how these endocrine disruptors suppress uterine gland 
development are not clear, but may be partially associated with reduced uterine epithelial 
cell proliferation and/or altered expression of Wnt genes [317]. TGFB signaling 
regulates multiple developmental events, and several lines of evidence suggest a link 
between estrogen action and TGFB signaling pathways in various types of cells 
including uterine cells [340-343]. In addition, TGFB signaling interacts with Wnts [344]. 
Since overactivation of TGFB signaling reduces uterine gland formation, it is tantalizing 
to speculate that TGFB signaling may partially mediate the adverse effect of endocrine 
disruptors on uterine gland development through regulating adenogenic genes. However, 
further investigation is warranted to identify a potential link.  
 
Although the primary focus of this study targeted uterine development and function, we 
noted histological alterations of the adult ovary. The role of TGFB signaling in the ovary 
remains largely unknown. To determine whether potential ovarian defects contribute to 
the observed infertility phenotype of TGFBR1 Pgr-Cre CA mice, we performed a timed 
mating study and found that no blastocysts could be recovered from the TGFBR1 Pgr-
Cre CA uteri, but there were a reduced number of morula stage embryos (data not 
shown). Therefore, the ovarian defects of TGFBR1 Pgr-Cre mice could be a 
contributing factor to the reproductive failure observed in these mice. Counterintuitively, 
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the ovulatory potential seems to be integral in sexually immature mice based on a 
superovulation experiment. Of note, Pgr-Cre is expressed in granulosa cells within the 
preovulatory follicles and interpretation of the ovarian phenotype of TGFBR1 Pgr-Cre 
CA mice should take into account the differentiation status of granulosa cells and the 
timing of Cre expression. Therefore, the observed ovarian defect in adult mice may 
reflect a cumulative effect of constitutive activation of TGFBR1, as opposed to the 
superovulation results obtained from pre-pubertal mice where Pgr-Cre activity is 
expected to be minimal before gonadotropin stimulation. An independent study is 
currently ongoing to characterize the role of over-activation of TGFBR1 in the mouse 
ovary.   
 
Collectively, our results show that constitutive activation of TGFBR1 in the uterus leads 
to morphological abnormalities and functional deficiencies in the uterus. These findings 
further reinforce the importance of a precisely controlled TGFB signaling system in 
normal uterine development and function. 
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4. CONDITIONAL ABROGATION OF TRANSFORMING GROWTH FACTOR 
BETA RECEPTOR 1 IN PTEN-INACTIVATED ENDOMETRIUM PROMOTES 
ENDOMETRIAL CANCER PROGRESSION IN MICE* 
 
4.1 Introduction 
Approximately 61,380 new cases and 10,920 deaths from uterine corpus cancers, the 
majority of which are endometrial cancers, are projected to occur in 2017 in the United 
States [223]. There are two major types of endometrial cancer. Type I cancers are mostly 
endometrioid adenocarcinomas that are associated with excess estrogen. Type II cancers 
are mainly composed of serous carcinomas which are estrogen independent, with overall 
poorer prognoses [345]. The mechanisms of endometrial cancer development are not 
well defined and effective prophylactic and therapeutic approaches are needed. 
Therefore, understanding the molecular mechanisms underlying the pathogenesis of 
endometrial cancer is an essential step toward developing novel targeted therapies [346]. 
 
Phosphatase and tensin homolog (PTEN), a tumor suppressor gene, is mutated in a 
variety of human cancers including endometrioid adenocarcinoma. PTEN suppresses 
activity of the phosphoinositide 3-kinase (PI3K)-AKT signaling pathway by 
dephosphorylating phosphatidylinositol (3, 4, 5)-trisphosphate (PIP3) that participates in 
                                                 
* Reprinted in slight modified form with permission from “Conditional abrogation of 
transforming growth factor beta receptor 1 in PTEN-inactivated endometrium promotes 
endometrial cancer progression in mice” by Gao Y, Lin P, Lydon JP, Li Q. J Pathol 
2017; 10.1002/path.4930 
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AKT activation. The PI3K-AKT signaling pathway regulates diverse cellular functions 
including, but not limited to, growth, survival, and metabolism and its abnormal 
activation is associated with cancer development [347]. Heterozygous Pten mice develop 
neoplasms in multiple organs [348]. Conditional deletion of Pten in the mouse uterus 
using progesterone receptor (Pgr)-Cre leads to endometrial cancer formation, supporting 
a pivotal role of PTEN in endometrial oncogenesis [349].   
 
Cancer cells, particularly those arising from advanced malignancies, can metastasize 
from the primary site to secondary site(s). Metastasis, consisting of a series of events 
including local invasion, intravasation, circulation, extravasation, and colonization, is the 
major cause of morbidity and mortality in cancer patients [350]. To establish distant 
metastasis, cancer cells originating from the primary site acquire an enhanced ability to 
migrate and invade. Myometrial invasion is an important factor for the diagnosis and 
staging of endometrial cancer. The depth of myometrial invasion has been used as a 
criterion for staging endometrial cancers by the International Federation of Gynecology 
and Obstetrics (FIGO), where FIGO stages IA and IB refer to endometrial cancers with 
no or less than half myometrial invasion and those with half or more than half 
myometrial invasion, respectively [351]. Moreover, a higher risk of extra-uterine 
metastases has been found in endometrial cancer patients with more than 50% 
myoinvasion compared to those with less than 50% myoinvasion [352]. Endometrial 
cancer can metastasize to other organs, with the common sites being lymph nodes, 
vagina, peritoneum, and lung [353, 354]. It has been increasingly recognized that the 
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cancer microenvironment is critical for metastasis by promoting adhesion, survival, 
extracellular matrix proteolysis, cell migration/invasion, immune escape, and 
angiogenesis [355]. Chemokines and their receptors are important regulators of many 
cancer cell properties such as proliferation, invasion, apoptosis, and metastasis [356]. 
Moreover, tumor-associated macrophages (TAMs), a major population of infiltrating 
leukocytes and well-known immunosuppressive cells, promote cancer growth, invasion, 
and metastasis [357]. Of note, metastasis has not been reported in the mouse model of 
endometrial cancer with uterine Pten depletion [349, 358], indicating a need to create 
additional models to study the metastatic process and associated mechanisms of this 
gynecologic malignancy.  
 
Transforming growth factor beta (TGFB) signaling is known to be tumor suppressive. 
Many essential elements of this pathway including the ligands, receptors, and SMAD 
transducers are mutated and/or altered in human diseases including cancers [359]. In 
vitro studies suggest that TGFB signaling regulates endometrial cancer cell proliferation, 
survival, invasion, and metastasis [360-362]. However, the contribution of TGFB 
signaling to the pathogenesis of endometrial cancer at the organismic level remains to be 
uncovered. Therefore, this study explores the role of TGFB signaling in endometrial 
cancer development and progression by creating a mouse model that harbors concurrent 
deletion of Tgfbr1 and Pten in the uterus. 
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4.2 Materials and methods 
4.2.1 Animals 
Mice were on a mixed C57BL/6/129 genetic background and the use of mice for this 
study was approved by the Institutional Animal Care and Use Committee at Texas A&M 
University. The Pgr-Cre and Tgfbr1flox mice were generated previously [238, 299]. The 
Pgr-Cre mice were obtained from Drs. John Lydon and Francesco DeMayo, while the 
Tgfbr1flox mice were contributed by Dr. Stefan Karlsson and imported from the 
laboratory of Dr. Martin Matzuk at Baylor College of Medicine. The Ptenflox mice were 
purchased from The Jackson Laboratory (stock # 006440; Bar Harbor, ME, USA) [363]. 
Genotypes of mice and DNA recombination were analyzed by genomic PCR (Appendix 
B-1) [238, 363].   
 
4.2.2 Histology, immunohistochemistry, and immunofluorescence 
Tissue samples were fixed in 10% neutral buffered formalin (Sigma, St. Louis, MO, 
USA), embedded in paraffin, and cut into 5 µm sections for hematoxylin-eosin (H & E) 
staining, immunohistochemistry, or immunofluorescence as described [364]. Antibody 
information is listed in Appendix B-2. 
 
4.2.3 Western blots 
Western blots were conducted as described [364] using primary antibodies (Appendix B-
2). Quantification of western blot was performed using NIH Image J (version 1.50i). 
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Data are presented as percentage, where the levels of target protein in Ptend/d mice were 
set to 100%.  
 
4.2.4 Enzyme-linked immunosorbent assay (ELISA) 
Concentrations of CXCL5 in serum were measured using the Quantikine ELISA kit 
(R&D, Minneapolis, MN, USA) according to the manufacturer’s instructions. Briefly, 
mouse serum samples were diluted 1:20 and assayed in duplicate, along with CXCL5 
controls and working standards. Upon completion of the assay, the optical density (OD) 
value of each well was measured by a microplate reader (BioTek, Winooski, VT, USA) 
at the wavelength of 450 nm and 540 nm. The OD values were corrected by subtracting 
readings at 540 nm from those at 450 nm. Concentrations of CCL2 in serum were 
determined using a mouse MCP-1/CCL2 ELISA Kit (Sigma) according to 
manufacturer’s protocol. The concentration of CCL2 in each sample was calculated 
using an online software (http://elisaanalysis.com).  
 
4.2.5 RNAscope 
The RNAscope 2.5 HD detection reagent (brown) and mouse Tgfbr1 probe (catalog No. 
406201) were purchased from Advanced Cell Diagnostics (ACD, Newark, CA, USA) 
and the analysis was performed according to the manufacturer’s instructions. Briefly, 
paraffin sections were deparaffinized, pretreated by boiling, and digested using protease 
before hybridization. Hybridization of Tgfbr1 probe was carried out at 40°C for 2 h, 
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followed by a series of amplification steps. The signals were detected using 3,3'-
diaminobenzidine (DAB).  
 
4.2.6 RNA isolation, reverse transcription, and quantitative real-time PCR 
Mouse uterine tissues were homogenized in RNA lysis tissue (RLT) buffer (Qiagen, 
Redwood City, CA, USA). Total RNA was isolated using a RNeasy Mini Kit (Qiagen) 
based on the manufacturer’s protocol, with on-column DNase digestion. The resultant 
RNA was dissolved in ribonuclease-free water. Reverse transcription was carried out 
using 200 ng (uterus) or 1 µg (lung) RNA and superscript III reverse transcriptase 
(ThermoFisher Scientific, Waltham, MA, USA). Quantitative real-time PCR was 
conducted using Bio-Rad Real-time PCR Detection System (Hercules, CA, USA). Each 
assay was performed at least in duplicate using primers (Appendix B-1) and iTaq 
Universal SYBR Green Supermix (Bio-Rad) [242]. 
 
4.2.7 Statistical analysis 
Statistical analysis was performed using GraphPad Prism (version 7.01). Data are mean 
± standard error of the mean (s.e.m.). Comparisons between two means were performed 
using two-tailed t-tests (unpaired). Comparisons of means among multiple groups were 
performed by one-way analysis of variance (ANOVA) followed by Holm-Sidak pairwise 
comparisons. Survival curve was analyzed by Log-rank/Mantel-Cox test. Significantly 
skewed data were log transformed prior to ANOVA. Statistical significance was defined 
as *P < 0.05, **P < 0.01, and ***P < 0.001. 
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4.3 Results 
4.3.1 Generation of mice harboring simultaneous deletion of the Pten and Tgfbr1 
genes 
Pten Pgr-Cre conditional knockout (termed Ptend/d) mice develop endometrial cancer 
[349]. To define the function of TGFB signaling in endometrial cancer, we 
simultaneously ablated the Pten and Tgfbr1 genes in the mouse uterus using Pgr-Cre. To 
examine the expression of Tgfbr1 in Ptend/d uteri, we performed RNAscope and 
demonstrated the localization of Tgfbr1 mRNA to the hyperplastic uterine epithelia in 
Ptend/d uteri (Appendix A-12A, B). Positive and negative controls were used (Appendix 
A-12C, D). To validate these models, we demonstrated that Pten and Tgfbr1 conditional 
alleles were recombined in the uteri, but not the tails, of Ptend/d and/or Ptend/d; Tgfbr1d/d 
mice (Appendix A-13A). A significant reduction in expression of Pten and/or Tgfbr1 
mRNAs was detected in uteri of Ptend/d, Tgfbr1d/d, and Ptend/d; Tgfbr1d/d mice by real-
time PCR analysis (Appendix A-13B-D). Reductions in abundance of PTEN in the uteri 
of Ptend/d; Tgfbr1d/d mice was demonstrated using immunohistochemistry and western 
blot analyses (Appendix A-13E-G, K). Consistent with the loss of inhibition of the 
PI3K-AKT pathway, phospho-AKT (pAKT) levels were increased in PTEN-depleted 
uteri (Appendix A-13H-K). Thus, we successfully created a mouse model with 
conditional deletion of Pten and Tgfbr1 in the uterus. 
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Figure 17. Simultaneous deletion of Pten and Tgfbr1 in the uterus leads to severe 
endometrial lesions at an early age. (A) Survival rates for Tgfbr1f/f (n = 14), Ptenf/f (n = 
12), Ptenf/f; Tgfbr1f/f (n = 10), Tgfbr1d/d (n = 19), Ptend/d (n = 13), and Ptend/d; Tgfbr1d/d 
(n = 25) mice. Note the reduced lifespan of Ptend/d; Tgfbr1d/d mice compared with 
Tgfbr1f/f, Ptenf/f, Ptenf/f; Tgfbr1f/f, Tgfbr1d/d, and Ptend/d mice. P < 0.0001 (Log-
rank/Mantel-Cox test). (B) Macroscopic analysis of uterine cancer from 8-week-old 
Ptend/d and Ptend/d; Tgfbr1d/d mice. Note that the uterine cancer from Ptend/d; Tgfbr1d/d 
mice was hemorrhagic and locally invasive compared with that from Ptend/d mice. 
Tgfbr1f/f, Tgfbr1d/d, Ptenf/f, and Ptenf/f; Tgfbr1f/f uteri were morphologically normal. 
Scale bar = 10 mm.  
 94 
 
 
Figure 18. Enhanced tumor progression in mice with uterine ablation of TGFBR1 and 
PTEN. (A-H) Immunostaining for ECAD in the uteri of Ptenf/f, Ptenf/f; Tgfbr1f/f, Ptend/d, 
and Ptend/d; Tgfbr1d/d mice at 2 and 4 weeks of age. Note the increased epithelial 
hyperplasia at 2 weeks of age (D) and formation of adenocarcinoma foci with necrosis at 
4 weeks of age in some Ptend/d; Tgfbr1d/d mice (H) versus Ptend/d mice (C, G). A lower 
magnification was used for E-H versus A-D to capture full images of uterine sections at 
4 weeks of age. (I-P) Immunostaining of ER and PGR in the uteri of Ptenf/f, Ptenf/f; 
Tgfbr1f/f, Ptend/d, and Ptend/d; Tgfbr1d/d mice. Signals were developed using NovaRED. 
Sections were counterstained with hematoxylin. Arrows indicate epithelial components 
lacking PGR expression (P). Immunohistochemistry was performed using at least three 
independent samples per genotype. Scale bar is representatively depicted in (A) and 
equals 100 µm (A-D), 250 µm (E-H), and 25 µm (I-P). 
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4.3.2 Ptend/d; Tgfbr1d/d mice develop severe endometrial lesions that progress more 
rapidly compared to mice with Pten deletion alone 
Endometrial cancer affects the lifespan of Pten d/d mice beginning around 5 months of 
age [349]. While all Ptend/d, Tgfbr1d/d, Tgfbr1f/f, Ptenf/f, and Ptenf/f; Tgfbr1f/f mice 
survived past 17 weeks, the Ptend/d; Tgfbr1d/d mice had significantly shortened lifespans 
(Figure 17A). Consistent with cancer development, the uterus/body weight ratio was 
increased in both Ptend/d and Ptend/d; Tgfbr1d/d mice versus Tgfbr1f/f, Ptenf/f, Ptenf/f; 
Tgfbr1f/f, and Tgfbr1d/d mice at both 4 and 9 weeks of age (Appendix A-14A, B). The 
uterine cancer in Ptend/d; Tgfbr1d/d mice was generally more hemorrhagic and/or locally 
invasive (Figure 17B). Tgfbr1d/d mice did not develop endometrial cancer despite the 
presence of cystic endometrial glands and adenomyosis in 8-month-old mice (data not 
shown). Thus, this mouse line was not included in subsequent studies. 
 
To determine potential phenotypic differences in endometrial cancer development 
between Ptend/d and Ptend/d; Tgfbr1d/d mice, we performed H & E staining and 
immunohistochemical analyses of E-cadherin (ECAD), an epithelial marker, using uteri 
from Ptend/d, Ptend/d; Tgfbr1d/d, and corresponding control mice at various ages. Atypical 
endometrial hyperplasia was found at the age of 10 days (not shown) and at 2 weeks in 
both Ptend/d and Ptend/d; Tgfbr1d/d mice (Appendix A-15A-F). Dramatic differences 
between Ptend/d; Tgfbr1d/d and Ptend/d mice were not found at 2 weeks of age, except for 
the presence of more hyperplastic epithelia in some Ptend/d; Tgfbr1d/d mice (Figure 18A-
D; Appendix A-15A-F). At the age of 4 weeks, the atypical endometrial hyperplasia in 
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Ptend/d mice progressed to carcinoma. In contrast, Ptend/d; Tgfbr1d/d mice developed 
more severe lesions with the presence of large foci of adenocarcinoma accompanied by 
degenerating cells within its central region in some mice (Figure 18E-H; Appendix A-
15G-L). Of note, endometrial cancers in both Ptend/d and Ptend/d; Tgfbr1d/d mice were 
positive for estrogen receptor (ER) and PGR at this stage (Appendix A-16A-H). 
However, a reduction of PGR, but not ER signals was observed in Ptend/d; Tgfbr1d/d mice 
at a later stage (Figure 18I-P; Appendix A-16I). At the age of 2 months, although 
myoinvasion could be observed in both Ptend/d and Ptend/d; Tgfbr1d/d mice (Appendix A-
17A-D), Ptend/d; Tgfbr1d/d uteri demonstrated a haphazard glandular pattern, 
desmoplastic stroma, and more severe myometrial disruption (Appendix A-17E, F; 
Figure 19A-E). Immunohistochemical analysis using a smooth muscle marker, calponin 
1 (CNN1), revealed that Ptend/d mice had recognizable myometrial layers at 2 months of 
age (Figure 19A, B, E), while severely disrupted myometrial layers intermingled with 
epithelial cancer cells were found in approximately 69% of Ptend/d; Tgfbr1d/d mice 
(Figure 19C, D, E). No myometrial abnormality was found in Tgfbr1d/d andTgfbr1f/f mice 
at the examined time stages (data not shown). To better visualize epithelial and 
myometrial compartments, we performed double immunofluorescence using anti-
cytokeratin 8 (KRT8) and CNN1 antibodies to label the respective epithelium and 
smooth muscle (Figure 19F-M). The results revealed that cancer epithelia breached the 
uterine wall in Ptend/d; Tgfbr1d/d mice (Figure 19J-M) versus Ptend/d mice (Figure 19F-I). 
Thus, these results provide in vivo evidence of accelerated endometrial cancer 
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progression and enhanced cell invasion in mice with conditional deletion of Pten and 
Tgfbr1. 
  
 
Figure 19. Myometrial invasion in Ptend/d; Tgfbr1d/d mice. (A-E) Immunohistochemical 
analysis of myometrial integrity using uteri from Ptend/d and Ptend/d; Tgfbr1d/d mice. 
Representative images of CNN1 staining (9 wk) are shown in panels (A-D) and a 
summary chart is provided in panel (E). Ptend/d (n = 12) and Ptend/d; Tgfbr1d/d (n = 13) 
mice at 8 and 9 weeks of age were utilized. (F-M) Double immunofluorescence of KRT8 
and CNN1 using uteri of 9-week-old Ptend/d and Ptend/d; Tgfbr1d/d mice. Note the severe 
myometrial invasion/disruption in Ptend/d; Tgfbr1d/d mice compared with Ptend/d mice. 
LM, longitudinal muscle layer; CM, circular muscle layer; Ep, epithelial cells. DAPI 
was used to counterstain nuclei. Scale bar is representatively depicted in (A) and equals 
100 µm (B, D, F-M) and 500 µm (A, C). 
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Figure 20. Conditional deletion of Pten and Tgfbr1 promotes endometrial cancer 
metastasis. (A) Gross analysis of lung metastases in 7-week-old Ptend/d; Tgfbr1d/d mice 
versus age-matched Ptenf/f; Tgfbr1f/f mice. Note the lungs from Ptend/d; Tgfbr1d/d mice 
were occupied with tumor foci versus those from Ptenf/f; Tgfbr1f/f mice. Scale bar = 10 
mm. (B-G) Histological analysis of the lungs from Ptend/d; Tgfbr1d/d and Ptenf/f; Tgfbr1f/f 
mice. Note the presence of highly organized alveoli structures (B) and metastatic 
nodules containing neoplasms with variable differentiation status (C-G) in the lungs of 
Ptenf/f; Tgfbr1f/f and Ptend/d; Tgfbr1d/d mice, respectively. (H-O) Immunohistochemical 
staining of lungs from Ptenf/f; Tgfbr1f/f and Ptend/d; Tgfbr1d/d mice at 9 weeks of age. 
Note the metastatic sites were positive for KRT8 (I), ER (K), and MUC1 (O), but not 
PGR (M). Immunohistochemistry was performed using at least 4 independent lung 
samples per genotype. The scale bar is representatively depicted in (B) and equals 20 µm 
(B-O). 
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4.3.3 Ptend/d; Tgfbr1d/d mice develop pulmonary metastasis  
Metastasis is a major cause of death in endometrial cancer patients [353, 354]. In 
contrast to the Ptend/d mice where visible metastasis in distant organs was not observed 
even at 25-36 weeks of age (Appendix B-3), Ptend/d; Tgfbr1d/d mice developed distant 
organ metastasis, preferentially in the lung. At the advanced stage of disease 
development (i.e., 7-16 weeks), no grossly visible metastases were observed in the 
bladder, heart, kidney, and spleen (Appendix B-3), although microscopically detectable 
metastases positive for KRT8 and ER could be found in the lymph nodes of Ptend/d; 
Tgfbr1d/d and Ptend/d mice (Appendix A-18). In contrast, grossly visible metastases were 
evident in the lungs of Ptend/d; Tgfbr1d/d mice (Figure 20A; Appendix A-19A, Appendix 
B-3). Unlike the lungs of Ptend/d mice comprising highly organized alveoli structures 
(Figure 20B), the lungs of Ptend/d; Tgfbr1d/d mice demonstrated multiple metastatic sites, 
consisting of pathological lesions with variable differentiation status (Figure 20C-G). In 
addition, the metastasis was frequently accompanied by hemorrhage and loss of 
morphologically normal alveoli (Appendix A-19A; Figure 20C-G). Using 
immunohistochemistry, we further verified that the metastatic nodules were positive for 
KRT8 (Figure 20I; Appendix A-19C) and ER (Figure 20K), but were negative for PGR 
(Figure 20M). Of note, analysis of ER expression in the lungs of Ptend/d; Tgfbr1d/d mice 
demonstrated the formation of endometrial gland-like lesions within the metastatic 
nodules (Appendix A-19D, E). Furthermore, recombined Tgfbr1/Pten conditional alleles 
were detected in the lung metastases of Ptend/d; Tgfbr1d/d mice, but not in the lung tissues 
of Ptend/d mice (Appendix A-19F). The metastatic nodules also expressed mucin 1 
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(MUC1; Figure 20O), a protein that is frequently over-expressed in metastatic cancers 
[365]. Immunostaining of the lungs from Ptenf/f; Tgfbr1f/f controls were representatively 
shown (Figure 20H, J, L, N). To confirm that pulmonary metastasis was specific to 
Ptend/d; Tgfbr1d/d mice, we analyzed age-matched lungs from Ptend/d and Ptenf/f mice and 
did not find metastasis in those mice (data not shown).  
 
4.3.4 Loss of TGFBR1 increases the production of pro-inflammatory chemokines 
associated with cancer metastasis 
Chemoattractant cytokines, or chemokines, and their receptors play important roles in 
many carcinogenic events [366]. To determine the potential mechanism of metastasis 
resulting from ablation of TGFBR1, we compared uterine expression of mRNAs for 
chemokines including C-X-C motif ligand 1 (Cxcl1), Cxcl5, Cxcl12, chemokine (C-C 
motif) ligand 2 (Ccl2), and Ccl9 and a chemokine receptor Cxcr2 that are involved in 
metastasis [367-370] between Ptend/d; Tgfbr1d/d and Ptend/d mice, along with Ptenf/f; 
Tgfbr1f/f and Ptenf/f controls. Results showed that the transcript levels of Cxcl5 and its 
receptor Cxcr2 were increased in the uteri of Ptend/d; Tgfbr1d/d mice versus Ptend/d and 
control mice at 2 weeks of age (Figure 21B, D), while those of Cxcl1 (Figure 21A), 
Cxcl12 (Figure 21C), Ccl2 (Figure 21E), and Ccl9 (Figure 21F) were comparable 
between Ptend/d; Tgfbr1d/d and Ptend/d mice at this time-point. To determine whether 
there was a correlation between concentrations of CXCL5 in serum and cancer 
progression and metastasis, we performed ELISA and demonstrated significantly greater 
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concentrations of CXCL5 in serum of Ptend/d; Tgfbr1d/d mice versus Ptend/d and control 
mice at 9 weeks of age (Figure 21G).  
 
 
Figure 21. Alteration of pro-inflammatory chemokine and receptor in Ptend/d; Tgfbr1d/d 
uteri. (A-F) Expression of select chemokines and receptor in the mouse uterus. Note that 
expression of Cxcl5 and Cxcr2 mRNA was increased in 2-week-old Ptend/d; Tgfbr1d/d 
mice versus Ptend/d and control mice. Ptenf/f and Ptenf/f; Tgfbr1f/f mice were included as 
normal controls. Real-time PCR was performed using CT method. Rpl19 was used as 
internal control. n = 4-9. (G, H) Serum CXCL5 and CCL2 levels in 9-week-old mice 
measured by ELISA. n = 5. Data are mean ± s.e.m. *P < 0.05, **P < 0.01, and ***P < 
0.001. Ns, P ≥ 0.05. (I) Increased mRNA levels of Ccl2 and Cxcl5 in the lungs of 
Ptend/d; Tgfbr1d/d mice versus Ptend/d mice at 9 weeks of age. n = 4. Data are mean ± 
s.e.m. *P < 0.05. (J, K) Immunostaining of CXCL5 in the lungs of 9-week-old Ptend/d 
and Ptend/d; Tgfbr1d/d mice. Immunohistochemistry was performed using at least four 
independent lung samples per genotype. Scale bar is representatively shown in (J) and 
equals 20 µm (J, K). 
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Figure 22. Expression of F4/80 and CD163 in mice with uterine deletion of Tgfbr1 and 
Pten. (A-D) Immunostaining of F4/80 and CD163 in the uteri of Ptend/d and Ptend/d; 
Tgfbr1d/d mice at 9 weeks of age. Five independent samples per genotype were 
examined. (E, F) Representative positive and negative controls for 
immunohistochemistry. Panel (E) shows a positive control for F4/80 antibody using liver 
tissues from 9-week-old Ptenf/f mice, while panel (F) is a negative control using rabbit 
IgG. The scale bar is representatively depicted in (A) and equals 20 µm (A-F). (G, H) 
Western blot analysis of CD163 protein expression in uteri of 9-week-old Ptend/d and 
Ptend/d; Tgfbr1d/d mice. Images for CD163 and GAPDH (internal control) are depicted in 
panel (G) and quantification results are shown in panel (H). Each lane represents an 
independent sample. Data are presented as percentages, where CD163 protein levels in 
Ptend/d mice were set to 100%. n = 4. Data are mean ± s.e.m. *P < 0.05.  
 
Interestingly, serum CCL2 levels were also increased in 9-week-old Ptend/d; Tgfbr1d/d 
mice (Figure 21H). Further analysis revealed significantly up-regulated expression of 
Ccl2 and Cxcl5 mRNAs in the lung metastases of 9-week-old Ptend/d; Tgfbr1d/d mice 
versus age-matched Ptend/d mice (Figure 21I), suggesting that lung metastases may serve 
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as a potential source of the elevated serum levels of these chemokines. Furthermore, 
CXCL5 was localized to the metastatic nodules within the lungs of Ptend/d; Tgfbr1d/d 
mice versus Ptend/d mice (Figure 21J, K). These results suggest involvement of 
CXCL5/CCL2 in endometrial cancer progression in Ptend/d; Tgfbr1d/d mice.  
 
4.3.5 Recruitment of tumor-associated macrophages in Ptend/d; Tgfbr1d/d uteri 
TGFB signaling regulates CXCL5 secretion in mammary cancer cells and recruits 
immune cells including TAMs to promote tumor progression [368, 369]. TAMs can 
acquire a polarized M2 phenotype (i.e., M2 macrophage or alternatively activated 
macrophage) and promote tumor progression [371]. We therefore examined the potential 
involvement of TAMs in tumor progression in Ptend/d; Tgfbr1d/d mice by 
immunohistochemistry using antibodies directed to CD163 (a marker for M2 
macrophages) [372].  F4/80, a well-established marker of murine macrophage [373], was 
used to monitor the macrophage population in the uteri. The presence of F4/80+ 
macrophages was revealed in the stroma of both Ptend/d and Ptend/d; Tgfbr1d/d tumors at 
9 weeks of age (Figure 22A, C). Interestingly, cells positive for CD163 were readily 
detectable in the uteri of Ptend/d; Tgfbr1d/d mice versus Ptend/d mice (Figure 22B, D). 
Positive and negative controls were included (Figure 22E, F). Consistent with this 
immunohistochemical observation, western blot analysis showed that CD163 expression 
was increased significantly in Ptend/d; Tgfbr1d/d mice compared with Ptend/d mice (Figure 
22G, H). Immunostaining for F4/80 and CD163 using age-matched Ptenf/f and Ptenf/f; 
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Tgfbr1f/f mice was done and results are presented in Appendix A-20. These findings 
suggest a role for TAMs in endometrial cancer progression in Ptend/d; Tgfbr1d/d mice.  
 
4.4 Discussion  
Mutation or inactivation of TGFB signaling components has been associated with the 
development of a broad array of cancers [374]. Although a putative role for TGFB 
signaling in the pathogenesis of human endometrial cancer has long been proposed 
[375], the precise function of TGFB signaling in endometrial cancer development has 
remained elusive. PTEN mutations have been identified in a variety of cancers. Loss of 
PTEN, a negative regulator of the PI3K-AKT pathway, is involved in the oncogenesis of 
endometrial carcinoma [376]. Conditional deletion of Pten in the mouse uterus using 
Pgr-Cre leads to the development of endometrial malignancy, which phenocopies many 
pathological characteristics of the human endometrial cancer [349]. As a result, the 
Ptend/d mouse model has been used to study endometrial cancer development [358, 377, 
378]. However, Ptend/d mice do not develop visible organ metastasis, a cause of 
recurrence after surgical intervention for primary cancers. Recurrence of endometrial 
cancer resulting from either local or distant metastases is devastating. Endometrial 
cancer results in the highest frequency of pulmonary metastases (20-25%) versus other 
gynecologic cancers [353, 354]. Therefore, development of an endometrial cancer model 
with organ metastases mimicking human endometrial cancer is critical to understanding 
of metastatic initiation and progression.  
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Little is known about the potential interplay between TGFB signaling and PTEN during 
endometrial carcinogenesis although their interactions have been documented in other 
tumors [379, 380]. Inactivation of TGFB signaling and loss of growth inhibition are 
associated with the development of human endometrial cancer [228, 381]. It has been 
shown that mutations of TGFB signaling components including TGFB receptors and 
SMADs and alteration of TGFB signaling activity reflected by changes in gene 
expression and/or phosphorylation of key signaling proteins play a role in the 
pathoetiology of human endometrial cancer [205, 206, 228]. TGFBR1 has a 5.6% 
mutation and alteration rate in human endometrial cancer [206, 224]. As reported, 
cancerous human endometrium expresses lower levels of TGFBR1 protein [227, 228]. 
TGFBR2 is mutated/altered in 6.5% endometrial tumors [206, 224]. Results of studies 
from The Cancer Genome Atlas (TCGA) Research Network have also suggested 
alterations of several SMADs in human endometrial cancer [206, 224]. Of particular 
importance is the availability of the two endometrial cancer models (i.e., Ptend/d and 
Ptend/d; Tgfbr1d/d mice) that demonstrated distinct pulmonary metastatic outcomes 
depending on the status of a known TGFB signaling component (i.e., TGFBR1) in the 
PTEN-inactivated uterus. Therefore, the aforementioned mutations and/or dysregulation 
of TGFB signaling components in endometrial cancer and the development of 
pulmonary metastasis in Ptend/d; Tgfbr1d/d mice make this model a valuable tool to study 
the pathogenesis and progression of endometrioid adenocarcinoma, the most frequent 
type of endometrial cancer in women. However, it needs to be pointed out that due to the 
expression of Pgr-Cre in uterine stromal cells and the myometrium, a potential impact of 
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TGFBR1 and/or PTEN loss in these cellular compartments on the tumor phenotype 
cannot be excluded, which may represent a limitation of the current study. Future 
investigations are needed to address this question using Cre lines targeting distinct 
cellular compartments of the uterus. 
 
Metastasis is a complex process where cancer cells can disseminate via the bloodstream 
and/or lymphatics to establish secondary tumors at the metastatic sites. Because of the 
invlovment of chemokines in the process of metastasis, therapeutic strategies targeting 
the action of chemokines may block/attenuate metastasis. A functional link between 
TGFB signaling and chemokines during cancer metastasis has emerged [367, 382, 383]. 
In one study, conditional ablation of TGFBR2 in mammary fibroblasts increased the 
secretion of CCL2, which promoted mammary cancer progression at least partially 
through a TAM-dependent mechanism [367]. Enhanced production of CCL9 resulting 
from loss of TGFB signaling promotes immature myeloid cell infiltration and the 
development of invasive intestinal tumors [384]. Loss of TGFB signaling in mouse 
mammary epithelial cells promotes metastasis by recruiting myeloid-derived suppressor 
cells into tumor tissues via the CXCL5-CXCR2 and CXCL12-CXCR4 axes [368]. The 
increased transcript levels of Cxcl5 and its receptor Cxcr2 in uteri of Ptend/d; Tgfbr1d/d 
mice suggest a potential common mechanism for CXCL5/CCL2 up-regulation in the 
absence of TGFB receptor-mediated signaling in epithelial cancer cells [368]. This 
finding, together with the role of CXCL5 in cell invasion and metastasis in several types 
of cancers including bladder cancer [385], mammary cancer [368], and liver cancer 
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[386], suggests that activation of the CXCL5-CXCR2 axis due to loss of TGFBR1 may 
contribute to the pulmonary metastasis of endometrial cancer induced by conditional 
abrogation of PTEN in the uterus. Importantly, we showed that serum levels of CXCL5 
and CCL2 were elevated in Ptend/d; Tgfbr1d/d mice compared with Ptend/d mice. Since 
CXCL5 expression is increased in human endometrial cancer tissues compared with 
normal endometrium [387], it is plausible to further explore the potential of CXCL5 and 
CCL2 as biomarkers for endometrial cancer patients.  
 
Studies using genetically modified mice have revealed the emerging role of TAMs in the 
development of invasive endometrial cancer [388, 389]. However, the involvement of 
uterine TGFB signaling in TAM recruitment and polarization and the contribution of 
TAMs to the development of endometrial cancer remains to be elucidated. At advanced 
stages of tumor development, CD163+ cells were readily detectable and the expression 
of CD163 was increased in the uteri of Ptend/d; Tgfbr1d/d mice versus Ptend/d mice, 
suggesting the involvement of TAMs in promoting endometrial cancer progression in 
Ptend/d; Tgfbr1d/d mice. Future studies are warranted to define the mechanism of action 
of pro-inflammatory chemokines, particularly CXCL5 and CCL2, and the function of 
TAMs within the tumor microenvironment in our model. It is noteworthy that TGFB 
signaling may act as tumor suppressor in pre-malignant cells, but tumor promoter during 
advanced tumor development [325]. That deletion of Tgfbr1 in the PTEN-inactivated 
uterus accelerates endometrial cancer progression and also highlights the complex role 
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of TGFB signaling in vivo, where compensatory pathways may function to promote 
cancer invasion/metastasis in the absence of TGFBR1.     
 
In summary, conditional deletion of Pten and Tgfbr1 leads to a disease that recapitulates 
invasive and lethal endometrial cancer. This new mouse model is potentially valuable for 
preclinical testing of targeted therapies to treat endometrial cancer with metastasis. 
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5. SUMMARY 
 
Uterine dysfunction can cause infertility. Therefore, understanding the mechanisms 
underlying the uterine development and function is an important issue. A variety of 
reproductive and developmental processes are regulated by a family of growth factors 
named as transforming growth factor beta (TGFβ) superfamily. These growth factors 
signal through the receptor complexes and intracellular canonical and/or noncanonical 
signaling to regulate multiple cellular events. Conditional knockout (cKO) of TGFβ type 
1 receptor (TGFBR1) in the female reproductive tract using anti-Müllerian hormone 
receptor type 2 (Amhr2)-Cre results in disrupted myometrial formation, suggesting that 
TGFβ signaling is critical for uterine development and function 
 
The first study of this dissertation was aimed at defining the cellular and molecular basis 
for myometrial defects in the Tgfbr1 cKO mice. We found that TGFBR1 is required for 
myometrial configuration/formation during early development. Despite the well-
established role of TGFβ signaling in vascular smooth muscle cell differentiation, the 
majority of smooth muscle genes were expressed in Tgfbr1 cKO uteri at similar levels as 
controls, coinciding with the presence but abnormal distribution of proteins for select 
smooth muscle markers. Importantly, the uteri of these mice had impaired synthesis of 
key extracellular matrix proteins collagen IV and laminin, and dysregulated expression 
of platelet-derived growth factors. Furthermore, platelet-derived growth factors induced 
the migration of uterine stromal cells from both control and Tgfbr1 cKO mice in vitro. 
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Our results suggest that the myometrial defects in Tgfbr1 cKO mice may not directly 
arise from an intrinsic deficiency in uterine smooth muscle cell differentiation, but are 
linked to the impaired production of key extracellular matrix components and abnormal 
uterine cell migration during a critical time window of postnatal uterine development. 
These findings will potentially aid in the design of novel therapies for reproductive 
disorders associated with myometrial defects. 
 
In the second study, to complement the loss of function model in the first study, we 
generated a gain-of-function mouse model harboring a constitutively active (CA) 
TGFBR1, the expression of which was conditionally induced by the progesterone 
receptor (Pgr)-Cre recombinase. Over-activation of TGFβ signaling was verified by 
enhanced phosphorylation of SMAD2 and increased expression of TGFβ target genes in 
the uterus. TGFBR1 Pgr-Cre CA mice were sterile. Histological, cellular, and molecular 
analyses demonstrated that constitutive activation of TGFBR1 in the mouse uterus 
promoted the formation of thicker myometrium. Accompanying this phenotype was the 
upregulation of a battery of smooth muscle genes in the uterus. Furthermore, TGFβ 
ligands activated SMAD2/3 and stimulated the expression of a smooth muscle maker 
gene, ACTA2, in human uterine smooth muscle cells. Immunofluorescence microscopy 
identified a marked reduction of uterine glands in TGFBR1 Pgr-Cre CA mice within the 
endometrial compartment that contained myofibroblast-like cells. We then demonstrated 
decidualization defects in the TGFBR1 Pgr-Cre CA mice using artificial decidualization 
approaches. Thus, constitutive activation of TGFBR1 in the mouse uterus leads to 
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morphological abnormalities and functional deficiency of the uterus. These results 
suggest a balanced TGFβ signaling system is required for normal uterine development 
and function. 
 
Although a putative role for TGFβ signaling in the pathogenesis of human endometrial 
cancer has long been proposed, the precise function of TGFβ signaling in the 
development and progression of endometrial cancer remains elusive. Depletion of PTEN 
in the mouse uterus causes endometrial cancer. In the third study, we focused on 
identifying the role of TGFB signaling in PTEN-inactivated uterine epithelial cells by 
deleting Tgfbr1 and Pten in the mouse uterus using Pgr-Cre (termed Ptend/d; Tgfbr1d/d). 
We found that Ptend/d; Tgfbr1d/d mice developed severe endometrial lesions that 
progressed more rapidly compared with those resulting from conditional deletion of Pten 
alone, suggesting that TGFβ signaling synergizes with PTEN to suppress endometrial 
cancer progression. Remarkably, the Ptend/d; Tgfbr1d/d mice developed distant 
pulmonary metastases. Mechanistically, the uteri and lung metastases of Ptend/d; 
Tgfbr1d/d mice had increased production of pro-inflammatory chemokines such as 
CXCL5 and CCL2. The severe myometrial invasion and disruption in Ptend/d; Tgfbr1d/d 
mice suggested enhanced epithelial cell migration/invasion in Ptend/d; Tgfbr1d/d mice. 
Furthermore, tumor-associated macrophages were recruited to the endometrial 
compartment of Ptend/d; Tgfbr1d/d mice that might promote tumor progression. Thus, 
conditional deletion of Tgfbr1 in PTEN-inactivated endometrium leads to more invasive 
 112 
 
endometrial cancer. This mouse model may be valuable for preclinical testing of new 
cancer therapies targeting tumor cell motility. 
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APPENDIX A 
 FIGURES 
 
A-1. Histological analysis of postnatal myometrial defects in Tgfbr1 cKO mice. (A-J) 
PAS-hematoxylin staining of uterine sections at P0 (A and B), P3 (C and D), P5 (E and 
F), P10 (G and H), and P15 (I and J) from control and Tgfbr1 cKO mice. Representative 
images are shown for each time point (n = 3). Red dotted lines indicate the circular 
smooth muscle layers in the control mice. Note the formation of circular myometrium in 
the controls during P3-P15, and the disorganized smooth muscle in the Tgfbr1 cKO 
mice. CM, circular smooth muscle layer; Ep, epithelium. Scale bar = 20 m. 
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A-2. Uterine adenomyosis in Tgfbr1 cKO mice. (A-D) Immunofluorescence of ACTA2 
(Red) in the uteri of a 3-month old control (A and C) and Tgfbr1 cKO mice (B and D). 
CM, circular smooth muscle layer; LM, longitudinal smooth muscle layer. (E and F) 
Immunohistochemical staining of CNN1 (brown staining) in the uteri of 3-month old 
control (E) and Tgfbr1 cKO mice (F). The sections were counter stained with 
hematoxylin. Representative images are shown for each group (n = 3). Note the 
disrupted myometrium and presence of uterine glands within the muscle layers (denoted 
by *) in the Tgfbr1 cKO mice compared with controls in which highly organized 
myometrium was visualized. Scale bar = 50 m. 
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A-3. Expression and localization of FN1 in the uteri of control and Tgfbr1 cKO mice. 
(A) Transcript levels of Fn1 in wild type uterus during postnatal uterine development at 
P0 (n = 5), P3 (n = 4), P5 (n = 3), P10 (n = 4), and P15 (n = 4). (B) Relative levels of 
mRNA for Fn1 in the uterus of control and Tgfbr1 cKO mice at P5 (n = 5 per group). 
Data are mean  SEM. NS, no significance. (C-F) Immunofluorescence of FN1 (green) 
and ACTA2 (red) in the uteri of control (C and D) and Tgfbr1 cKO (E and F) mice. CM, 
circular smooth muscle layer; Ep, epithelium. Scale bar = 20 m. 
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A-4. Abnormal distribution of vasculature in Tgfbr1 cKO uterus at P15. (A and B) 
Double immunofluorescence of CD31 (Red) and ACTA2 (Green) without (A) or with 
DAPI (Blue; B). Note that vessels were well organized and mostly distributed between 
circular and longitudinal muscle layers and within the endometrium on the cross section. 
(C-F) Double immunofluorescence of CD31 (Red) and ACTA2 (Green) without (C and 
E) or with DAPI (Blue; D and F). Arrows indicate uterine vessels. Note the presence of 
vessels inside the disrupted myometrial layers of the Tgfbr1 cKO uteri. (G and H) 
Representative negative controls where primary antibodies were replaced with rabbit (G) 
or mouse (H) IgG. Note no specific staining was detected in the absence of primary 
antibodies. CM, circular smooth muscle layer; LM, longitudinal smooth muscle layer. 
Scale bar (20 m) is representatively depicted in (A). 
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A-5. Impaired laminin production by myometrial cells during early uterine development. 
(A-F) Subcellular localization of laminin (Green; A and B), ACTA2 (Red; C and D), and 
laminin and ACTA2 (E and F) in the uteri of control mice at P5. (G-L) Subcellular 
localization of laminin (Green; G and H), ACTA2 (Red; I and J), and laminin and 
ACTA2 (K and L) in the uteri of Tgfbr1 cKO mice at P5. Note the lack of typical 
laminin immunofluorescence signals in the smooth muscle cells of Tgfbr1 cKO mice (G-
L) compared with controls (A-F). Representative images are shown for each group (n = 
3). The yellow dotted lines indicate the circular smooth muscle layers developed at P5. 
CM, circular smooth muscle layer; LAM, laminin. Scale bar = 20 m. 
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A-6. Histology of uterine samples from control and TGFBR1 Pgr-Cre CA mice. Uteri 
from control and TGFBR1CA Lox/Lox; Pgr-Cre mice were stained with hematoxylin and 
eosin and representative images are shown. Scale bar = 250 m (A and C) and 100 m 
(B and D). 
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A-7. Immunofluorescence analysis of endometrial glandular and stromal alterations 
during early postnatal uterine development. (A-L) Immunolocalization of cytokeratin 8 
(KRT8; green) or KRT8 and smooth muscle actin (ACTA2; red) in the uteri of control 
(Ctrl) and TGFBR1 Pgr-Cre CA mice at postnatal day 5 (PD5; A-D), PD7 (E-H), PD15 
(I-L). Note the distinct staining pattern of ACTA2 between Ctrl and TGFBR1 Pgr-Cre 
CA mice, and a reduction of uterine glands marked by KRT8 in the TGFBR1 Pgr-Cre 
CA mice versus Ctrl. (M-P) Immunofluorescence staining of forkhead box A2 (FOXA2; 
red) in the uteri of Ctrl and TGFBR1 Pgr-Cre CA mice at PD15. Yellow arrows (M-P) 
indicate the localization of FOXA2. DAPI (blue) was used to counterstain the nuclei. 
Scale bar is representatively shown in (A) and equals 50 µm (A-H), 100 µm (I-M, and 
O), and 25 µm (N and P). 
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A-8. Immunohistochemistry analysis of luminal epithelial cell proliferation at postnatal 
day 7. (A-D) Immunohistochemistry of ki67 in the uteri of control (Ctrl) and TGFBR1 
Pgr-Cre CA (CA) mice at postnatal day 7 (D7). Panels (C and D) represent higher 
magnification images for corresponding panels (A and B). Note the extensive luminal 
epithelial cell proliferation in both Ctrl and TGFBR1 Pgr-Cre CA mice. Scale bar equals 
100 µm (A and B), and 20 µm (C and D). 
 
 175 
 
 
 
A-9. Expression analysis of genes encoding WNT signaling pathway components in 
TGFBR1 Pgr-Cre CA mice. Transcript levels of Wnt4 (A), Wnt5a (B), Wnt7a(C), 
Wnt11(D), Wnt16(E), catenin beta 1 (Ctnnb1) (F), frizzled homolog 6 (Fzd6) (G), and 
Fzd10(H) in the uteri of control and TGFBR1 Pgr-Cre CA mice at postnatal day 7 (D7) 
(n = 4), D15 (n = 5 for control group, n = 4 for TGFBR1 Pgr-Cre CA group), D31 (n = 
4). Quantitative PCR was performed using CT method. Rpl19 was used as an internal 
control. Data are means ± S.E.M. *P<0.05. 
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A-10. Up-regulation of pro-fibrotic genes in TGFBR1 Pgr-Cre CA uteri. Transcript 
levels of Ctgf (A), Col1a1 (B), Lama1(C), Itga1(D), and Itgb1(E) in the uteri of control 
and TGFBR1 Pgr-Cre CA mice at postnatal day 7 (D7) (n = 4), D15 (n = 5 for control 
group, n = 4 for TGFBR1 Pgr-Cre CA group), D31 (n = 4). Quantitative PCR was 
performed using CT method. Rpl19 was used as an internal control. Data are means ± 
S.E.M. *P<0.05. 
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A-11. TGFB ligand induces the expression of genes associated with extracellular matrix 
deposition/function and smooth muscle cell property in uterine stromal cells. (A-E) 
TGFB1 (5ng/ml) induced mRNA expression of Ctgf; (A), Lama1 (B), Itga1 (C), Acta2 
(D) and Des (E) in uterine stromal cells. Uterine stromal cells were isolated and cultured 
overnight, serum starved, and treated with TGFB1. Cells were collected after 4h and 20 
h of treatment and processed for quantitative PCR analysis using CT method. 
Ribosomal protein L19 (Rpl19) was used as an internal control. Data represent results 
from three independent experiments. Data are means ± S.E.M. *P<0.05. 
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A-12. Localization of Tgfbr1 mRNA expression in Ptend/d uteri. (A-D) RNAscope 
analysis of Tgfbr1 mRNA localization (A, B) along with positive (C) and negative (D) 
controls. Panel (B) is a higher magnification image for panel (A). Scale bar is 
representatively shown in (A) and equals 10 µm (B) and 15 µm (A, C, D). Ep, 
epithelium; St, stroma. 
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A-13. Validation of Tgfbr1, Pten, and Tgfbr1/Pten conditional knockout mice. (A) 
Analysis of recombination of Pten/Tgfbr1 conditional alleles using tails and uteri from 
9-week-old control, Ptend/d, Tgfbr1d/d, and Ptend/d; Tgfbr1d/d mice. (B-D) Reduction of 
Pten and/or Tgfbr1 mRNA levels in the uteri of 2-week-old Ptend/d, Tgfbr1d/d, and 
Ptend/d; Tgfbr1d/d mice compared with corresponding controls. Quantitative real-time 
PCR was performed using CT method. Rpl19 was used as internal control. Data are 
mean ± s.e.m. n = 4. **P < 0.01 and ***P < 0.001. Ns, P ≥ 0.05. (E-K) Reduced 
expression of PTEN and increased expression of pAKT in Ptend/d; Tgfbr1d/d uteri. Note 
the reduced signal intensity of PTEN staining, but increased expression of 
immunoreactive pAKT in the uteri of 2-week-old Ptend/d; Tgfbr1d/d mice using 
immunohistochemical analysis (E-J). The immunoreactive signals were developed using 
NovaRED. Immunohistochemistry was performed using independent samples from 3 
mice per genotype. Ep, epithelia; St, stroma. Scale bar is representatively depicted in (E) 
and equals 15 µm (E, F, H, I) and 10 µm (G, J). Results were further verified by western 
blot using uterine protein lysates (n = 4; K). 
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A-14. Gross analysis of endometrial cancer development. (A, B) Ratios of the 
uterus/body weight (BW) in Tgfbr1f/f, Ptenf/f, Ptenf/f; Tgfbr1f/f, Tgfbr1d/d, Ptend/d, and 
Ptend/d; Tgfbr1d/d mice at 4 and 9 weeks of age. Note the significantly increased 
uterus/body weight ratio of Ptend/d; Tgfbr1d/d mice compared with that of Ptend/d mice at 
9 weeks of age. n = 4-7 for (A) and n = 5 for (B). Data are mean ± s.e.m. ***P < 0.001. 
Ns, P ≥ 0.05. 
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A-15. Histological analysis of endometrial cancer development. (A-L) H & E staining of 
the uteri from Ptend/d and Ptend/d; Tgfbr1d/d mice at 2 and 4 weeks of age. Ptenf/f and 
Ptenf/f; Tgfbr1f/f mice (not shown) were included as controls. Panels (D-F) and (J-L) 
represent higher power images for panels (A-C) and (G-I), respectively. H & E staining 
was performed using at least 3 independent samples per genotype. Scale bar is 
representatively depicted in (A) and equals 200 µm (A-C, G-I) and 20 µm (D-F, J-L).  
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A-16. Expression of ER and PGR in mouse uteri with conditional deletion of Pten and/or 
Tgfbr1. (A-H) Immunostaining of ER and PGR in the uteri of 4-week-old Ptenf/f, Ptenf/f; 
Tgfbr1f/f, Ptend/d, and Ptend/d; Tgfbr1d/d mice. Immunoreactive signals were developed 
using NovaRED. The sections were counterstained with hematoxylin. Results represent 
experiments using 3 independent samples per genotype. Scale bar is representatively 
depicted in (A) and equals 20 µm (A-H). (I) Western blot analysis of PGR protein 
expression in the uteri of Ptend/d and Ptend/d; Tgfbr1d/d mice at 9 weeks of age. 
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A-17. Histological analysis of tumor development and myometrial invasion. (A-F) H & 
E staining of uterine sections from Ptend/d and Ptend/d; Tgfbr1d/d mice at ~2 months of 
age. Note myometrial invasion was detected in both Ptend/d and Ptend/d; Tgfbr1d/d mice 
although the latter tended to be more severe, culminating in myometrial disruption and 
unrecognizable myometrial layers (see Figure 19). Desmoplastic stroma and haphazard 
glandular pattern were also observed in Ptend/d; Tgfbr1d/d uteri (E, F). H & E staining 
was performed using independent samples from Ptend/d (n = 12) and Ptend/d; Tgfbr1d/d (n 
= 13) mice. CM, circular muscle layer; LM, longitudinal muscle layer. Asterisks indicate 
epithelial invasion. Dotted yellow line marks the epithelial lesions within the 
myometrium. Scale bar is representatively depicted in (A) and equals 100 µm (A, C, E) 
and 25 µm (B, D, F). 
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A-18. Identification of endometrial cancer metastasis in lymph nodes. (A-L) 
Immunohistochemical staining of KRT8 and ER using iliac lymph node tissues from 
control, Ptend/d, and Ptend/d; Tgfbr1d/d mice. Note that no KRT8 and ER expression was 
detected in control lymph nodes (A, B, G, H). However, metastases positive for KRT8 
and ER were found in the lymph nodes of both Ptend/d (C, D, I, J) and Ptend/d; Tgfbr1d/d 
mice (E, F, K, L). Immunohistochemistry was performed using 9-16 week old Ptend/d 
and Ptend/d; Tgfbr1d/d mice (n = 4). Signals were developed using NovaRED. The 
sections were counterstained with hematoxylin. Arrows indicate metastases. Panels (B, 
D, F, H, J, L) represent higher power images for corresponding panels (A, C, E, G, I, K). 
Scale bar is representatively depicted in (A) and equals 100 µm (A, C, E, G, I, K) and 25 
µm (B, D, F, H, J, L). 
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A-19. Lung metastasis in Ptend/d; Tgfbr1d/d mice. (A) Gross analysis of lung metastases 
in 9-week-old Ptend/d; Tgfbr1d/d mice. Note the lungs of Ptend/d; Tgfbr1d/d mice were 
occupied with tumor foci/nodules (arrows). (B, C) Immunohistochemical analysis of 
KRT8 staining using lungs from 9-week-old control and Ptend/d; Tgfbr1d/d mice. Dotted 
yellow line indicates metastatic lesions in the lungs of Ptend/d; Tgfbr1d/d mice. (D, E) 
Immunohistochemical analysis of ER staining using lungs from 9-week-old Ptend/d; 
Tgfbr1d/d mice. Images represent different microscopic fields of a lung sample from the 
same mouse. Arrows indicate endometrial gland-like structures within the metastatic 
sites of the lungs. Immunoreactive signals were developed using NovaRED. The 
sections were counterstained with hematoxylin. Scale bar is representatively depicted in 
(B) and equals 100 µm (B, C) and 25 µm (D, E). (F) Analysis of recombination of 
Pten/Tgfbr1 conditional alleles using lungs from Ptend/d and Ptend/d; Tgfbr1d/d mice at 9 
weeks of age. Neg, no-template control. Note the recombined Pten/Tgfbr1 conditional 
alleles were only detected in the lung metastases of Ptend/d; Tgfbr1d/d mice but not in the 
lung tissues of Ptend/d mice, supporting that the epithelial lesions in the lungs of Ptend/d; 
Tgfbr1d/d mice were derived from the primary uterine tumors.  
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A-20. Expression of F4/80 and CD163 in control uteri. (A-D) Immunostaining of F4/80 
and CD163 using uteri from Ptenf/f and Ptenf/f; Tgfbr1f/f mice at 9 weeks of age. 
Immunoreactive signals were developed using NovaRED. The sections were 
counterstained with hematoxylin. Uterine samples from 5 mice per genotype were 
examined. Scale bar is representatively depicted in (A) and equals 20 µm (A-D). 
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APPENDIX B 
 TABLES 
 
B-1. Primers for conventional PCR and quantitative real-time PCR 
 
Target Sequence (5-3) Source 
Tgfbr1flox Forward ACTCACATGTTGGCTCTCACTGTC [179] 
 Reverse AGTCATAGAGCATGTGTTAGAGTC  
Ptenflox Forward CAAGCACTCTGCGAACTGAG The Jackson  
 Reverse AAGTTTTTGAAGGCAAGATGC Laboratory 
Pgr-Cre Forward TATACCGATCTCCCTGGACG [147] 
 Reverse ATGTTTAGCTGGCCCAAATG  
 Reverse CCCAAAGAGACACCAGGAAG  
Tgfbr1d Forward ATTTCTTCTGCTATAATCCTGCAG [390] 
 Reverse AGTCATAGAGCATGTGTTAGAGTC  
Ptend Forward ACTCAAGGCAGGGATGAGC [363] 
 Reverse AATCTAGGGCCTCTTGTGCC  
 Reverse GCTTGATATCGAATTCCTGCAGC  
Hprt Forward GGACCTCTCGAAGTGTTGGATAC [179] 
 Reverse CTTGCGCTCATCTTAGGCTT  
Tgfbr1 Forward TGCCATAACCGCACTGTCA [179] 
 Reverse AATGAAAGGGCGATCTAGTGATG  
Pten Forward TGAAGACCATAACCCACCACA [391] 
 Reverse TCATTACACCAGTCCGTCCCT  
Cxcl1 Forward TGGCTGGGATTCACCTCAAGAACA [392] 
 Reverse TGTGGCTATGACTTCGGTTTGGGT  
Cxcl5 Forward GCATTTCTGTTGCTGTTCACGCTG [393] 
 Reverse CCTCCTTCTGGTTTTTCAGTTTAGC  
Cxcl12 Forward CCAGAGCCAACGTCAAGCAT [394] 
 Reverse CAGCCGTGCAACAATCTGAA  
Cxcr2 Forward ATGCCCTCTATTCTGCCAGAT PrimerBank ID 
 Reverse GTGCTCCGGTTGTATAAGATGAC 6753456a1 
Ccl2 Forward TTAAAAACCTGGATCGGAACCAA PrimerBank ID 
 Reverse GCATTAGCTTCAGATTTACGGGT 6755430a1 
Ccl9 Forward CCCTCTCCTTCCTCATTCTTACA PrimerBank ID 
 Reverse AGTCTTGAAAGCCCATGTGAAA 6755434a1 
Rpl19 Forward ATGAGTATGCTCAGGCTACAGA [242] 
 Reverse GCATTGGCGATTTCATTGGTC  
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B-2. Primary antibodies for immunostaining and western blot 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B-3. Visible metastasis at advanced tumor stage in Ptend/d; Tgfbr1d/d versus Ptend/d mice 
 
 
 
 
Name Manufacturer Catalog no. Host IHC/IF Western
PTEN Cell Signaling 9559 Rabbit 1:400 1:1000 
Phospho-AKT Cell Signaling 4060 Rabbit 1:50 1:2000 
AKT Cell Signaling 4691 Rabbit  1:1000 
GAPDH Cell Signaling 2118 Rabbit  1:1000 
KRT8 DSHB TROMA-1 Rat 1:200  
ECAD Cell Signaling 3195 Rabbit 1:400  
ER Santa Cruz sc-542 Rabbit 1:1000  
PGR Thermo Scientific RB-9017 Rabbit 1:200 1:1000 
CNN1 Millipore 04-589 Rabbit 1:500  
CD163 Abcam ab182422 Rabbit 1:1000 1:1000 
F4/80 AbD Serotec MCA497GA Rat 1:200  
CXCL5 Bioss bs-2549R Rabbit 1:800  
MUC1 Novus Biologicals NB120-15481 Rabbit 1:200  
Organ/tissue Ptend/d 
 (n = 7; 25-36 wks) 
Ptend/d; Tgfbr1d/d 
(n = 16; 7-16 wks) 
Lung 0 15 
Liver 0 1 
Spleen 0 0 
Kidney 0 0 
Heart 0 0 
Peritoneum 0 2 
Bladder 0 0 
